The original disclosure in Japanese was released on May 9, 2017 at 16:00 (GMT+9)

Consolidated Financial Statements for the Year Ended March 31, 2017
FY2017(April 1, 2016 - March 31, 2017) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listing: Tokyo Stock Exchange (1st section)
Code Number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Investor Relations Dept.
TEL : (075)241-5124
Scheduled date of general shareholders' meeting: June 29, 2017
Scheduled date of starting delivery of dividends: June 30, 2017

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the year ended March 31, 2017 (April 1, 2016 – March 31, 2017)

(1) Operating results

Note: Percentages indicated changes from the previous fiscal year.

	Year ended March 31, 2017		Year ended March 31, 2016	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	234,193	3.9	225,364	2.7
Operating income	13,551	16.0	11,680	5.3
Ordinary income	14,344	11.7	12,840	8.6
Net income (loss) attributable to owners of the parent	8,480	20.2	7,055	23.6
Net income per share (Yen)	42.15		35.06	
Fully diluted net income per share (Yen)	-		-	
Return on equity		6.4		5.4
Ordinary income to total assets ratio		5.4		5.0
Operating income to net sales ratio		5.8		5.2
Note: Comprehensive income	7,784	268.7	2,111	(84.7)
Reference: Income (loss) from equity method investment	268		334	

(2) Financial position

	As of March 31, 2017	As of March 31, 2016
	(Millions of yen)	(Millions of yen)
Total assets	274,368	253,253
Net assets	165,920	156,148
Equity ratio (%)	49.2	51.5
Net assets per share (Yen)	671.11	647.97
Reference: Equity	135,043	130,386

(3) Cash flow

	Year ended March 31, 2017	Year ended March 31, 2016
	(Millions of yen)	(Millions of yen)
Cash flow from operating activities	12,826	10,373
Cash flow from investing activities	16,200	(10,864)
Cash flow from financing activities	(2,828)	(9,482)
Cash and cash equivalents, end of year	58,765	32,536

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2016	Year ended March 31, 2017	Year ending March 31, 2018(Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	12.0	13.0	14.00
Annual	12.0	13.0	14.00
Total dividend (Millions of yen)	2,414	2,615	
Payout ratio (%)	34.2	30.8	33.1
Dividend on equity (%)	1.8	2.0	

Note: The year-end dividend for FY2016 included a commemorative dividend of ¥1.00

3. Forecast for the year ending March 31, 2018 (April 1, 2017 – March 31, 2018)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2017		Year ending March 31, 2018	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	125,000	16.3	268,000	14.4
Operating income	4,700	(9.7)	14,000	3.3
Ordinary income	4,700	(16.3)	14,400	0.4
Net income attributable to owners of the parent	2,400	(24.5)	8,500	0.2
Net income attributable to owners of the parent per share (Yen)	11.93		42.24	

4. Others

(1) Changes in subsidiaries during the period (changes in specified subsidiaries resulting in change of scope) : Yes
Newly included: 1 (Name) Nippon Food Supplies Company Pty Ltd

(2) Changes in accounting policies, accounting estimates and retrospective restatement
1) Changes based on revisions of accounting standard : Yes
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(3) Number of outstanding shares (common stock)
1) Number of outstanding shares at year end (Treasury stocks are included)
As of March 31, 2017 : 217,699,743
As of March 31, 2016 : 217,699,743
2) Number of treasury stocks at year end
As of March 31, 2017 : 16,475,731
As of March 31, 2016 : 16,475,391
3) Average number of outstanding shares
Year ended March 31, 2017 : 201,224,223
Year ended March 31, 2016 : 201,224,978

Contents of the attached document

1. Overview of Financial Results---------- 2
   (1) Overview of Financial Results for the Fiscal Year under Review---------- 2
   (2) Overview of Financial Position for the Fiscal Year under Review---------- 5
   (3) Overview of Cash Flows for the Fiscal Year under Review---------- 6
   (4) Future Outlook---------- 6
2. Basic concept on selection of accounting standards---------- 6
3. Consolidated Financial Statements and Important Notes---------- 7
   (1) Consolidated Balance Sheets---------- 7
   (2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income---------- 9
      Consolidated Statements of Income---------- 9
      Consolidated Statements of Comprehensive Income---------- 10
   (3) Consolidated Statements of Changes in Net Assets---------- 11
   (4) Consolidated Statements of Cash Flows---------- 13
   (5) Notes to Consolidated Financial Statements ---------- 14
      (Notes on Premise of Going Concern) ---------- 14
      (Changes in Accounting Policies)---------- 14
      (Additional information) ---------- 14
      (Segment Information) ---------- 15
      (Per Share Information) ---------- 17
      (Significant Subsequent Events) ---------- 17

○ Supplement for the Consolidated Financial Statements

1. Overview of Financial Results

(1) Overview of Financial Results for the Fiscal Year under Review

In the fiscal year under review, ended March 31, 2017, although the Japanese economy maintained a moderate recovery as the hiring and income environment improved, personal spending remained weak. Looking abroad, while the U.S. and European economies have continued to expand gradually, there was continued uncertainty for the future of the global economy owing to economic slowdowns in emerging countries, primarily China, the Brexit issue in the U.K, the impact of future policies in the U.S. and other issues.

Under these economic circumstances, moving into the final fiscal year of the Takara Group Medium-Term Management Plan FY2017, which is the second step of efforts toward achieving the Takara Group Vision 2020, our long-term vision, the Group continued to make efforts to improve domestic business profitability and to expand and grow our overseas business while working on steady business activities with aim of transforming into a well-balanced business structure that can hold up well to business environment changes by accelerating growth in our Biomedical Business.

As a result, in the fiscal year under review, ended March 31, 2017, net sales were up by 3.9% year on year to ¥234,193 million. Gross profit rose 5.0 % year on year to ¥94,010 million. Operating income increased by 16.0% year on year to ¥13,551 million while ordinary income rose 11.7% year on year to ¥14,344 million. Net income attributable to owners of the parent increased by 20.2% year on year to ¥8,480 million.

Results by business segment were as follows.

(Takara Shuzo Group)

In Japan, a severe competitive environment is expected to continue due to the decrease in consumption of alcoholic beverages because of the population decline and aging of society, the diversification of consumer preferences and an ongoing frugal mindset. Meanwhile, there have been new opportunities including expansion of the home-meal replacement and away-from-home meals markets owing to more women entering the workplace and increases in the number of elderly or single adult households.

Overseas, it has been expected that Japanese food markets will further grow primarily owing to increasing attention to Japanese foods and a global increase in the number of Japanese restaurants.

In this environment , the Takara Shuzo Group worked mainly on improving the earning power of its business in Japan by developing high-quality products differentiated by its technology and increasing its overseas business by expanding the overseas Japanese food wholesaler network mainly in the U.S. and Europe.

The segment's sales and other information are as follows:

[Alcoholic beverages]

Shochu

For *ko*-type shochu, the Takara Shuzo Group newly launched *Takara Shochu NIPPON*, which uses 3% cherry barrel-aged shochu and domestic Japanese cherry leaves as part of its raw materials, achieving a refreshing flavor and faintly sweet fragrance reminiscent of *sakuramochi* (rice cakes filled with red bean paste and wrapped in a cherry leaf). For *Honkaku* shochu, the Takara Shuzo Group worked on revitalizing the *Ikkomon* brand, such as renewing the *Ikkomon* design to promote the quality of its use of 100% sweet potatoes and strengthen its premium impression.

Overall shochu net sales, however, decreased 2.3% year on year to ¥58,001 million, affected by the shrinking shochu market.

Sake

Although the domestic sake market has been in a severe state with a continuing decline in consumption, the Takara Shuzo Group continued to work on expanding sales of *Sho Chiku Bai Shirakabe-gura Mio Sparkling Sake*, which the Takara Shuzo Group has positioned as the most important strategic product and focused on. The Takara Shuzo Group also renewed the flavor of *Sho Chiku Bai Ten*, maintaining the full-bodied, refreshing dry flavor produced via a two-stage brewing process while aiming for an even dryer experience and more refreshing aftertaste.

Furthermore, in the commercial market, the Takara Shuzo Group continued to work on expanding sales of *Sho Chiku Bai Gokai*, which is a product only for sale to restaurants and bars.

As a result, overall sake net sales increased 0.3% year on year, to ¥24,822 million.

Light-alcohol refreshers

The Takara Shuzo Group continued to work to expand sales of dry flavored chu-hi *Takara Shochu High Ball*, positioned a flagship brand. For *Takara Can Chu-Hi*, the Takara Shuzo Group newly released *Takara Can Chu-Hi Dry*, which is characterized by the punch of 9% alcohol content, zero sugar, zero purines, zero sweeteners, and a dry flavor. The Takara Shuzo group also worked on expanding sales, such as by actively launching various flavored light-alcohol refreshers of other brands.

Consequently, overall light-alcohol refreshers net sales increased 10.7% year on year, to ¥30,796 million.

Other alcoholic beverages

In Japan, Japanese-made whiskey demonstrated steady results. Overseas, Age International, Inc. (U.S.A) recorded sales increases for *Bourbon whiskey*, but sales of products such as wine and synthetic sake declined, and accordingly, net sales of other alcoholic beverages were down 0.4% year on year to ¥14,116 million.

As a result, total alcoholic beverages net sales increased 1.3% year on year, to ¥127,737 million.

[Seasonings]

In addition to home-use seasonings and seasonings for use by restaurants and bars, the Takara Shuzo Group continued working to develop products, such as those based on user needs and highly functional ones differentiated by its own technology, for food processors and manufacturers of ready prepared meals, etc., sales to which have been expected to continue to grow into the future.

Sales of *Hon-Mirin* declined. As for other seasonings, driven by our salt-free, high-quality *Takara Ryori no Tame no Seishu*, sales of cooking sake continued to fare well, and food seasonings also increased due to focuses on expanding sales of soup, combined and other seasonings.

As a result, total seasonings net sales increased 1.3% year on year, to ¥24,741 million.

[Raw alcohol, etc.]

The Takara Shuzo Group continued to drastically revise prices together with working to expand the sales of industrial, contracted, and other alcohol.

As a result, raw alcohol, etc. net sales increased 8.0% year on year, to ¥7,771 million.

[Transportation]

The Takara Shuzo Group focused on the main transportation business and worked to win new customers. However, net sales in this business were down 12.9% year on year, to ¥10,635 million.

[Japanese food wholesale business in overseas markets]

As for Japanese food wholesale business in overseas markets, the Takara Shuzo Group continued to expand its presence in food service markets including away-from-home meals markets such as Japanese restaurants, home-meal replacement markets including takeout and ready prepared meals, and retail markets including supermarkets and grocery stores, mainly in Europe. The Takara Shuzo Group also took steps such as welcoming Keta Foods, Lda (Portugal) into the Group and strengthening its partnership with Mutual Trading Co., Inc. (U.S.A) to further expand its overseas Japanese food wholesaler network.

As a result of these efforts, net sales of Japanese food wholesale business in overseas markets increased 40.0% year on year, to ¥28,933 million.

[Other]

Other net sales decreased 5.8% year on year, to ¥1,352 million.

As a result, the Takara Shuzo Group's overall net sales increased 4.8% year on year to ¥201,171 million, with gross profit up 5.2% to ¥74,841 million, and SG&A expenses up 3.8% to ¥65,086 million following a rise in personnel expenses and promotion expenses, among others, resulting in operating income increased 16.0%, to ¥9,755 million.

(Takara Bio Group)

Utilizing biotechnology developed over many years, the Takara Bio Group concentrated management resources on three areas: the Bioindustry business, the Gene Therapy business, and the AgriBio business, and worked to improve business results.

Bioindustry business

As the Takara Bio Group's core business, the Bioindustry business mainly provides products and services that support research and development activities in biotechnology-related fields. Such activities are becoming increasingly widespread.

In the Bioindustry business, sales of research reagents and scientific instruments, its flagship products, declined in part due to the appreciation of the yen. Our contract research services business, however, increased in sales.

As a result of these above, net sales of the Bioindustry business declined 2.7% year on year, to ¥26,573 million.

Gene Therapy business

In the Gene Therapy business, the Takara Bio Group has been focusing efforts on early commercialization of gene therapy for cancer and other diseases utilizing the RetroNectin® Method, a highly efficient gene transduction technology; the RetroNectin® expansion-culture system, a highly efficient lymphocyte propagation technology; and proprietary technologies including siTCR.

In the fiscal year under review, ended March 31, 2017, ¥500 million in revenue relating to the oncolytic virus HF10 (HF10) was generated.

As a result of these above, net sales in the Gene Therapy business were ¥500 million (there were no sales in the Gene Therapy business in the previous fiscal year).

AgriBio business

Based on the concept of "food as medicine," this business uses its unique leading-edge biotechnology to identify the scientific basis of foodstuffs. Based on this evidence, it develops, manufactures, and sells functional food ingredients. The AgriBio business focuses on rolling out gagome kombu (kelp) "Fucoidan" related products, agar-derived agaro-oligosaccharide related products, ashitaba (angelica herb) "Chalcone" related products, the herb (Peucedanum japonicum) "Isosamidin" related products, yam (Dioscorea esculenta) "Yamsgenin™" related products, and mushroom-related products.

Health foods and mushroom related product sales declined, leading to AgriBio business net sales decreasing 4.4% year on year to ¥2,301 million.

As a result, the Takara Bio Group's overall net sales decreased 1.2% year on year, to ¥29,375 million with gross profit up 3.9% to ¥16,952 million, SG&A expenses up 0.7% to ¥13,749 million following expenses incurred in relation to share buybacks for U.S. WaferGen Bio-systems, Inc. and Rubicon Genomics, Inc., resulting in operating income increased 20.1% year on year, to ¥3,202 million.

(Takara Healthcare)

Under such conditions that the health food market was expected to expand further against the backdrop of increasing needs for better health due to population aging and a well-established system of foods with function claims, Takara Healthcare strove to expand sales in the mail-order sales business through aggressive and efficient advertising, focusing on the gagome kombu (kelp) "Fucoidan" series and the herb (Peucedanum japonicum) "Isosamidin" series.

With these actions, sales of "Isosamidin" related products increased, but those of "Fucoidan" related products remained flat from the previous fiscal year, and OEM cosmetics declined, with Takara Healthcare's net sales decreasing 5.3% year on year, to ¥1,766 million with gross profit up 12.8% to ¥1,097 million, SG&A expenses up 19.5% to ¥1,084 million following a rise in sales promotion and administrative expenses, resulting in operating income decreasing 80.3% year on year, to ¥12 million.

(Other)

In the other segment, which comprises functional corporate groups such as a printing business, net sales increased 2.0% year on year, to ¥5,924 million with gross profit up 13.7% to ¥829 million, and SG&A expenses up 2.6% to ¥689 million resulting in operating income increasing 142.1% to ¥140 million.

Breakdown of sales results by product category

Segment	Previous Fiscal Year (From April 1, 2015 to March 31, 2016)	Fiscal Year under Review (From April 1, 2016 to March 31, 2017)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	59,376	58,001	97.7
Sake	24,736	24,822	100.3
Light-alcohol refreshers	27,815	30,796	110.7
Other alcoholic beverages	14,170	14,116	99.6
Alcoholic beverages total	126,097	127,737	101.3
Hon Mirin	15,104	14,991	99.2
Other seasonings	9,314	9,749	104.7
Seasonings total	24,419	24,741	101.3
Raw alcohol, etc.	7,197	7,771	108.0
Transportation	12,204	10,635	87.1
Japanese food wholesales business in overseas markets	20,668	28,933	140.0
Other	1,436	1,352	94.2
Total	192,025	201,171	104.8
Takara Bio Group	29,729	29,375	98.8
Takara Healthcare	1,865	1,766	94.7
Other	5,809	5,924	102.0
Sales not allocated to business segments and intersegment transactions	(4,065)	(4,044)	-
Total	**225,364**	**234,193**	**103.9**

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Overview of Financial Position for the Fiscal Year under Review

(Assets)

At the end of the fiscal year under review, current assets were ¥173,912 million, an increase of ¥14,839 compared with that at the end of the previous fiscal year. This was primarily due to an increase in cash and deposits of ¥19,686 million, an increase in notes and accounts receivable-trade of ¥4,546 million and an increase in merchandise and finished goods of ¥5,560 million, as well as a decline in securities of ¥15,000 million. Noncurrent assets were ¥100,456 million, an increase of ¥6,276 million compared with that at the end of the previous fiscal year. This was primarily because of an increase in property, plant and equipment of ¥6,108 million.

As a result, total assets were ¥274,368 million, an increase of ¥21,115 compared with that at the end of the previous fiscal year.

(Liabilities)

At the end of the fiscal year under review, current liabilities totaled ¥65,506 million, an increase of ¥17,858 compared with that at the end of the previous fiscal year. This was mainly due to increases in notes and accounts payable-trade of ¥1,603 million, short-term loans payable of ¥4,212 million, and current portion of bonds of ¥10,000 million. Noncurrent liabilities were ¥42,941 million, a decrease of ¥6,514 million compared with that at the end of the previous fiscal year. This was primarily due to a ¥10,000 million decrease resulting from the transfer of bonds to current liabilities, whereas long-term loans payable increased by ¥741 million and deferred tax liabilities by ¥1,917 million, respectively.

As a result, total liabilities were ¥108,447 million, an increase of ¥11,343 million compared with that at the end of the previous fiscal year.

(Net Assets)

At the end of the fiscal year under review, total net assets were ¥165,920 million, an increase of ¥9,771 million compared with that at the end of the previous fiscal year. The main factors were increases of ¥6,066 million in retained earnings, ¥2,760 million in valuation difference on available-for-sale securities and ¥5,115 million in non-controlling interests, as well as a decline of ¥4,122 million in foreign currency translation adjustment.

As a result, equity ratio totaled 49.2%, compared with 51.5% at the end of the previous fiscal year.

(3) Overview of Cash Flows for the Fiscal Year under Review

Net cash provided by operating activities increased ¥2,452 million year on year, to ¥12,826 million primarily due to profit before income taxes of ¥14,520 million, depreciation and amortization of ¥5,171 million, an increase in notes and accounts receivable-trade of ¥1,334 million, an increase in inventories of ¥1,377 million and income taxes paid of ¥5,218 million.

Net cash provided by investment activities resulted in revenue of ¥16,200 million compared with an expenditure of ¥10,864 million in the previous fiscal year primarily due to payments into time deposits of ¥7,510 million, proceeds from the withdrawal of time deposits of ¥15,959, the purchase of securities of ¥10,059 million, proceeds from sales and redemption of securities of ¥22,028 million and purchase of property, plant and equipment and intangible assets of ¥5,376 million.

Net cash used in financing activities decreased by ¥6,653 million year on year primarily due to redemption of bonds of ¥5,000 million, although there were expenditures of ¥2,828 including cash dividends paid of ¥2,413 million.

As a result, cash and cash equivalents at fiscal year-end, including the effect of exchange rate change on cash and cash equivalents, stood at ¥58,765 million, up ¥26,228 million from the previous fiscal year-end.

(4) Future Outlook

While the domestic economy is facing continued improvement in the employment and income environment resulting in a gradual economic recovery, it is expected that the global economy will continue to be even more uncertain due to issues such as the effects of the policies taken by the new administration in the U.S., the influence of the Brexit matter in the U.K., and economic slowdowns in emerging countries, primarily China.

In this environment, the Company initiated the Takara Group Medium-Term Management Plan FY2020 in the fiscal year ending March 31, 2018, as the last step towards achieving its long-term Takara Group Vision 2020. By further increasing the overseas sales ratio together with having a full product line-up and many products with a competitive edge both in Japan and overseas, the Company is aiming to build up a great number of fields in which it can beat competitors and establish a balanced business foundation able to grow revenues significantly no matter what environmental changes occur.

As regards the outlook for results for the following fiscal year, the Group is forecasting a sales increase of 14.4% year on year to ¥268,000 million, an operating income increase of 3.3% year on year to ¥14,000 million, an ordinary income increase of 0.4% year on year to ¥14,400 million and an increase in net income attributable to owners of the parent of 0.2% year on year to ¥8,500 million.

Note that in accordance with the spinning off of the overseas business of Takara Shuzo Co., Ltd. dated July 3, 2017 and the establishment of Takara Shuzo International Co., Ltd., changes will be made to reportable segments. The Medium-Term Management Plan business strategies and outlook for the results in the coming fiscal year for each segment are as follows.

The aim for Takara Shuzo is to establish a firm position as the number one maker of Japanese alcoholic beverage in the domestic alcoholic beverage and seasonings markets by expanding sales and profit ratios in every category with a focus on sake. As concerns results for the coming fiscal year, the Takara Shuzo Group is forecasting an increase in net sales of 2.4% year on year to ¥153,000 million and an increase in operating income of 10.4% year on year to ¥5,600 million.

The aim for the Takara Shuzo International Group is to dramatically expand its scope of business by enlarging its overseas Japanese food wholesaler network, together with developing its business foundation and strengthening its position with the goal of becoming a leading company in the global Japanese alcoholic beverage and foods market. As concerns results for the coming fiscal year, the Takara Shuzo International Group is forecasting an increase in net sales of 67.8% to ¥63,000 million and an increase in operating income of 16.2% to ¥3,700 million.

The aim for the Takara Bio Group is to promote the strategies of the Bioindustry, Gene Therapy, and AgriBio business and strengthen the management bases which support these strategies to enhance its presence as a global company and manufacturer of regenerative medicine products. As concerns results for the coming fiscal year, the Takara Bio Group is forecasting an increase in net sales of 13.0% to ¥33,200 million and an increase in operating income of 3.0% to ¥3,300 million.

The above results forecast was created based on information obtainable at the time of the publication of this document and actual results may differ due to a variety of factors going forward.

2. Basic concept on selection of accounting standards

Disclosure is omitted due to the lack of any significant change from the details disclosed in the Consolidated Financial Statements for the Fiscal Year Ended March 31, 2014 (disclosed on May 8, 2014).

3. Consolidated Financial Statements and Important Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2016	As of Mar. 31, 2017
Assets		
Current assets		
Cash and deposits	38,386	58,073
Notes and accounts receivable-trade	46,845	51,392
Electronically recorded monetary claims-operating	6,756	6,558
Securities	28,238	13,237
Merchandise and finished goods	29,739	35,300
Work in process	1,077	1,244
Raw materials and supplies	3,401	3,306
Deferred tax assets	2,070	2,112
Other	2,788	2,922
Allowance for doubtful accounts	(231)	(236)
Total current assets	159,073	173,912
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	48,903	53,980
Accumulated depreciation	(31,168)	(33,028)
Buildings and structures, net	17,735	20,952
Machinery, equipment and vehicles	82,182	82,563
Accumulated depreciation	(69,627)	(70,247)
Machinery, equipment and vehicles, net	12,554	12,315
Land	18,118	20,089
Lease assets	1,483	2,056
Accumulated depreciation	(619)	(959)
Lease assets, net	863	1,096
Construction in progress	104	262
Other	12,812	14,609
Accumulated depreciation	(9,125)	(10,152)
Other, net	3,687	4,457
Total property, plant and equipment	53,065	59,174
Intangible assets		
Goodwill	6,975	6,626
Other	4,035	3,630
Total intangible assets	11,010	10,256
Investments and other assets		
Investment securities	24,747	25,583
Net defined benefit asset	874	896
Deferred tax assets	1,683	1,496
Other	2,910	3,140
Allowance for doubtful accounts	(112)	(90)
Total investments and other assets	30,103	31,025
Total noncurrent assets	94,179	100,456
Total assets	253,253	274,368

(Millions of Yen)

	As of Mar. 31, 2016	As of Mar. 31, 2017
Liabilities		
Current liabilities		
Notes and accounts payable-trade	15,201	16,804
Short-term loans payable	4,994	9,206
Current portion of bonds	—	10,000
Accrued alcohol tax	7,855	7,593
Accrued expenses	4,965	5,562
Income taxes payable	2,307	2,468
Provision for bonuses	2,235	2,449
Other provision	1,870	1,899
Other	8,217	9,521
Total current liabilities	47,648	65,506
Noncurrent liabilities		
Bonds payable	20,000	10,000
Long-term loans payable	10,255	10,996
Deferred tax liabilities	3,647	5,564
Net defined benefit liability	8,544	8,961
Long-term deposits received	5,379	5,342
Other	1,630	2,075
Total noncurrent liabilities	49,456	42,941
Total liabilities	97,104	108,447
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	1,879	1,650
Retained earnings	113,663	119,729
Treasury stock	(9,938)	(9,939)
Total shareholders' equity	118,830	124,667
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	6,822	9,583
Deferred gains or losses on hedges	(445)	0
Foreign currency translation adjustment	5,548	1,426
Remeasurements of defined benefit plans	(370)	(634)
Total accumulated other comprehensive income	11,555	10,375
Noncontrolling interests	25,762	30,877
Total net assets	156,148	165,920
Total liabilities and net assets	253,253	274,368

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(Millions of Yen)

	FY2016 (Apr. 1, 2015 – Mar. 31, 2016)	FY2017 (Apr. 1, 2016 – Mar. 31, 2017)
Net sales	225,364	234,193
Cost of sales	135,868	140,182
Gross profit	89,495	94,010
Selling, general and administrative expenses	77,815	80,458
Operating income	11,680	13,551
Non-operating income		
Interest income	301	193
Dividends income	446	465
Share of profit of entities accounted for using equity method	334	268
Subsidy income	471	288
Other	277	320
Total non-operating income	1,830	1,537
Non-operating expenses		
Interest expenses	447	481
Exchange loss	50	76
Other	172	186
Total non-operating expenses	671	744
Ordinary income	12,840	14,344
Extraordinary income		
Gain on step acquisitions	—	878
Gain on sales of noncurrent assets	21	206
Reversal of provision for loss on business liquidation	48	—
Other	283	41
Total extraordinary income	353	1,126
Extraordinary loss		
Impairment loss	281	667
Loss on sales and retirement of noncurrent assets	311	264
Other	51	18
Total extraordinary losses	644	950
Income before income taxes and minority interests	12,548	14,520
Income taxes-current	4,839	5,208
Income taxes-deferred	(60)	74
Total income taxes	4,778	5,283
Net income	7,769	9,236
Net income attributable to the noncontrolling interest	713	755
Net income attributable to owners of the parent	7,055	8,480

(Consolidated Statements of Comprehensive Income)

(Millions of Yen)

	FY2016 (Apr. 1, 2015 – Mar. 31, 2016)	FY2017 (Apr. 1, 2016 – Mar. 31, 2017)
Net income	7,769	9,236
Other comprehensive income		
Valuation difference on available-for-sale securities	(2,276)	2,760
Deferred gains or losses on hedges	(1,010)	446
Foreign currency translation adjustment	(2,300)	(4,310)
Remeasurements of defined benefit plans	(74)	(348)
Share of other comprehensive income of associates accounted for using equity method	4	—
Total other comprehensive income	(5,657)	(1,451)
Comprehensive income	2,111	7,784
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	1,820	7,300
Comprehensive income attributable to noncontrolling interest	291	483

(3) Consolidated Statements of Change in Net Assets

FY2016 (Apr. 1, 2015 – Mar. 31, 2016)

(Millions of Yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance at the beginning of current period	13,226	3,196	108,647	(9,937)	115,132
Changes of items during the period					
Dividends from surplus			(2,012)		(2,012)
Net income			7,055		7,055
Purchase of treasury stock				(1)	(1)
Disposal of treasury stock		0		0	0
Purchase of shares of consolidated subsidiaries		(1,316)			(1,316)
Change of scope of consolidation			(27)		(27)
Net changes of items other than shareholders' equity					
Total changes of items during the period	-	(1,316)	5,016	(1)	3,698
Balance at the end of current period	13,226	1,879	113,663	(9,938)	118,830

	Accumulated other comprehensive income					Minority interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	9,098	558	7,431	(297)	16,791	26,481	158,404
Changes of items during the period							
Dividends from surplus							(2,012)
Net income							7,055
Purchase of treasury stock							(1)
Disposal of treasury stock							0
Purchase of shares of consolidated subsidiaries							(1,316)
Change of scope of consolidation							(27)
Net changes of items other than shareholders' equity	(2,276)	(1,003)	(1,882)	(72)	(5,235)	(718)	(5,954)
Total changes of items during the period	(2,276)	(1,003)	(1,882)	(72)	(5,235)	(718)	(2,255)
Balance at the end of current period	6,822	(445)	5,548	(370)	11,555	25,762	156,148

FY2017 (Apr. 1, 2016 – Mar. 31, 2017)

(Millions of Yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance at the beginning of current period	13,226	1,879	113,663	(9,938)	118,830
Changes of items during the period					
Dividends from surplus			(2,414)		(2,414)
Net income			8,480		8,480
Purchase of treasury stock				(0)	(0)
Disposal of treasury stock		0		0	0
Purchase of shares of consolidated subsidiaries		(229)			(229)
Change of scope of consolidation					
Net changes of items other than shareholders' equity					
Total changes of items during the period	-	(229)	6,066	(0)	5,836
Balance at the end of current period	13,226	1,650	119,729	(9,939)	124,667

	Accumulated other comprehensive income					Minority interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	6,822	(445)	5,548	(370)	11,555	25,762	156,148
Changes of items during the period							
Dividends from surplus							(2,414)
Net income							8,480
Purchase of treasury stock							(0)
Disposal of treasury stock							0
Purchase of shares of consolidated subsidiaries							(229)
Change of scope of consolidation							
Net changes of items other than shareholders' equity	2,760	445	(4,122)	(264)	(1,179)	5,115	3,935
Total changes of items during the period	2,760	445	(4,122)	(264)	(1,179)	5,115	9,771
Balance at the end of current period	9,583	0	1,426	(634)	10,375	30,877	165,920

(4) Consolidated Statements of Cash Flows

(Millions of Yen)

	FY2016 (Apr. 1, 2015 – Mar. 31, 2016)	FY2017 (Apr. 1, 2016 – Mar. 31, 2017)
Net cash provided by (used in) operating activities		
Income before income taxes and minority interests	12,548	14,520
Depreciation and amortization	5,179	5,171
Impairment loss	281	667
Increase (decrease) in net defined benefit liability	140	419
Interest and dividends income	(747)	(659)
Interest expenses	447	481
Gain (loss) on step acquisitions	—	(878)
Decrease (increase) in notes and accounts receivable-trade	688	(1,334)
Decrease (increase) in inventories	(2,171)	(1,377)
Increase (decrease) in notes and accounts payable-trade	(239)	208
Increase (decrease) in liquor taxes payable	244	(261)
Increase (decrease) in accrued consumption taxes	(1,747)	478
Other, net	95	387
Subtotal	14,721	17,823
Interest and dividends income received	773	697
Interest expenses paid	(456)	(475)
Income taxes paid	(4,664)	(5,218)
Net cash provided by (used in) operating activities	10,373	12,826
Net cash provided by (used in) investing activities		
Payments into time deposits	(16,813)	(7,510)
Proceeds from withdrawal of time deposits	19,717	15,959
Purchase of securities	(13,112)	(10,059)
Proceeds from sales and redemption of securities	6,225	22,028
Purchase of property, plant and equipment and intangible assets	(5,743)	(5,376)
Purchase of securities	(60)	(11)
Purchase of investments in subsidiaries resulting in change in scope of consolidation	—	(1,327)
Proceeds from acquisition in subsidiaries resulting in change in scope of consolidation	—	2,070
Payments for sales of investments in subsidiaries resulting in change in scope of consolidation	(51)	—
Other, net	(1,026)	426
Net cash provided by (used in) investing activities	(10,864)	16,200
Net cash provided by (used in) financing activities		
Redemption of bonds	(5,000)	—
Cash dividends paid	(2,014)	(2,413)
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	(2,022)	—
Other, net	(445)	(415)
Net cash provided by (used in) financing activities	(9,482)	(2,828)
Effect of exchange rate change on cash and cash equivalents	(240)	31
Net increase (decrease) in cash and cash equivalent	(10,212)	26,228
Cash and cash equivalents at beginning of period	42,749	32,536
Cash and cash equivalents at end of period	32,536	58,765

(5) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Changes in Accounting Policies)

(Application of Practical Solution on a change in depreciation method due to Tax Reform 2016)

In the fiscal year under review, ended March 31, 2017, certain consolidated subsidiaries applied the Practical Solution on a change in depreciation method due to Tax Reform 2016 (PITF No. 32, June 17, 2016) following the revision of the Corporation Tax Act, and changed the method of depreciation for structures and facilities attached to buildings acquired on and after April 1, 2016 from the declining-balance method to the straight-line method.

The impact of this change on operating income, ordinary income, and profit before income taxes and minority interests for the fiscal year under review, ended March 31, 2017, is immaterial.

(Additional information)

(Application of Revised Implementation Guidance on Recoverability of Deferred Tax Assets)

The Company has been applying the Revised Implementation Guidance on Recoverability of Deferred Tax Assets (ASBJ Guidance No. 26 of March 28, 2016) from the beginning of the fiscal year under review, ended March 31, 2017.

(Changes to Reporting Segments)

In accordance with the spinning off of the overseas business of Takara Shuzo Co., Ltd. on July 3, 2017 and the establishment of Takara Shuzo International Co., Ltd., the three reporting segments of the Takara Shuzo Group, Takara Bio Group, and Takara Healthcare reported in the fiscal year under review, ended March 31, 2017, will be changed to the Takara Shuzo, Takara Shuzo International Group, and Takara Bio Group reporting segments in the fiscal year ending March 31, 2018.

Information concerning the sales, income and losses, assets, and other items for each reporting segment in the fiscal year under review, ended March 31, 2017 when converted to the post-change segments is as follows.

Fiscal Year under Review (From April 1, 2016, to March 31, 2017)

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo Group	Takara Shuzo International	Takara Bio Group	Subtotal				
Net sales								
External customers	149,408	37,278	28,529	215,216	18,976	234,193	0	234,193
Intersegment	44	262	845	1,152	20,041	21,193	(21,193)	-
Total	149,452	37,540	29,375	216,369	39,017	255,386	(21,193)	234,193
Segment income	5,071	3,182	3,202	11,456	2,167	13,624	(72)	13,551
Segment assets	90,931	64,759	67,143	222,834	23,061	245,895	28,472	274,368
Other items								
Depreciation and amortization	2,196	623	1,722	4,542	437	4,979	191	5,171
Amortization of goodwill	-	424	162	586	-	586	-	586
Investment in equity-method affiliates	-	-	-	-	-	-	1,407	1,407
Increase in total fixed assets, property, plant and equipment and intangible assets	2,188	763	1,648	4,600	666	5,267	1,391	6,658

Notes:
1. Other includes business segments that are not part of reported segments, such as the transportation business and other domestic Japanese Group companies and the Company's real estate leasing.
2. Details of adjustment amounts are as follows.
   (1) Net sales to external customers are income from contracting recognized by the Company.
   (2) Segment income comprises intersegment eliminations of ¥(61) million and losses of the Company not allocated to business segments of ¥(11) million.
   (3) Segment assets include assets of the Company not allocated to business segments of ¥47,963 million and other adjustment (principally eliminations) of ¥(19,490) million. Assets attributed to the Company include surplus funds and long-term investment assets.
   (4) Depreciation and amortization comprises depreciation and amortization recognized by the Company.
   (5) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.
   (6) Increase in total fixed assets, property, plant and equipment and intangible assets comprises increases recognized by the Company.
3. Segment income has been adjusted to the operating income of consolidated financial statements.

(Segment Information)

1. Overview of Reported Segments

Reporting segments are the segments of the Takara Group for which financial information can be obtained. The Board of Directors, top organization for decision making on Group management, examines such information to determine the allocation of management resources and evaluate the business performance on a regular basis.

The Group consists of the two corporate groups centered on the operating companies, Takara Shuzo Co., Ltd. and Takara Bio Inc., both of which were formed when the Company became a holding company; the Health food business, which is managed by Takara Healthcare Inc.; other businesses; and the Company, which manages the whole group as the holding company. All operating companies develop comprehensive business strategies, covering both domestic and overseas operations, for the products and services that they offer, and work to expand their business operations.

Accordingly, the Group has defined three reported segments based on its business segments, while taking into consideration the relationship of capital between each consolidated subsidiary, the scope of managerial responsibility, and of the capacity to evaluate business performance. These three reported segments are the Takara Shuzo Group, the Takara Bio Group, and Takara Healthcare.

The Takara Shuzo Group primarily engages in the manufacture and sale of alcoholic beverages and seasonings, as well as Japanese food wholesale businesses overseas. The Takara Bio Group engages in the manufacture and sale of products such as research reagents, scientific instruments, and mushrooms, as well as contract research services. Takara Healthcare engages in the sale of products such as health foods.

2. Calculation method for net sales, income or loss, assets, liabilities, and other items of each reported segment

The accounting treatment of reported business segments is generally the same as that explained in “Basis of Presentation of Consolidated Financial Statements.”

The figures for the income of reported segments are based on operating income. Intersegment income is based on the prevailing market price.

3. Net sales, Income (Loss), Assets and Other items by Reported Segment

Previous Fiscal Year (From April 1, 2015, to March 31, 2016)

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	191,736	28,818	1,863	222,419	2,484	224,903	461	225,364
Intersegment	288	910	1	1,200	3,325	4,526	(4,526)	-
Total	192,025	29,729	1,865	223,620	5,809	229,429	(4,065)	225,364
Segment income	8,410	2,667	64	11,142	58	11,200	480	11,680
Segment assets	150,773	66,591	712	218,077	5,685	223,762	29,490	253,253
Other items								
Depreciation and amortization	3,252	1,687	3	4,944	59	5,004	175	5,179
Amortization of goodwill	357	181	-	538	-	538	-	538
Investment in equity-method affiliates	3,052	-	-	3,052	-	3,052	1,322	4,375
Increase in total fixed assets, property, plant and equipment and intangible assets	2,919	2,090	5	5,015	368	5,383	620	6,003

Notes:
1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
   (1) Net sales to external customers are income from real estate rent recognized by the Company.
   (2) Segment income includes eliminations of ¥16 million and income of the Company not allocated to business segments of ¥464 million.
   (3) Segment assets include assets of the Company not allocated to business segments of ¥44,432 million and other adjustment (principally eliminations) of ¥(14,941) million. Assets attributed to the Company include surplus funds and long-term investment assets.
   (4) Depreciation and amortization comprises depreciation and amortization recognized by the Company.
   (5) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.
   (6) Increase in total fixed assets, property, plant and equipment and intangible assets comprises increases recognized by the Company.
3. Segment income has been adjusted to the operating income of consolidated financial statements.

Fiscal Year under Review (From April 1, 2016, to March 31, 2017)

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated financial statements (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	200,951	28,529	1,764	231,246	2,484	233,731	462	234,193
Intersegment	219	845	1	1,067	3,439	4,507	(4,507)	-
Total	201,171	29,375	1,766	232,313	5,924	238,238	(4,044)	234,193
Segment income (loss)	9,755	3,202	12	12,970	140	13,111	440	13,551
Segment assets	166,697	67,143	715	234,556	5,848	240,405	33,963	274,368
Other items								
Depreciation and amortization	3,191	1,722	4	4,919	59	4,978	192	5,171
Amortization of goodwill	424	162	-	586	-	586	-	586
Investment in equity-method affiliates	-	-	-	-	-	-	1,407	1,407
Increase in total fixed assets, property, plant and equipment and intangible assets	3,269	1,648	12	4,930	333	5,264	1,394	6,658

Notes:
1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
   (1) Net sales to external customers are income from real estate rent recognized by the Company.
   (2) Segment income includes eliminations of ¥62 million and income of the Company not allocated to business segments of ¥377 million.
   (3) Segment assets include assets of the Company not allocated to business segments of ¥49,681 million and other adjustment (principally eliminations) of ¥(15,718) million. Assets attributed to the Company include surplus funds and long-term investment assets
   (4) Depreciation and amortization comprises depreciation and amortization recognized by the Company.
   (5) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.
   (6) Increase in total fixed assets, property, plant and equipment and intangible assets comprises increases recognized by the Company.
3. Segment income has been adjusted to the operating income of consolidated financial statements.

(Per Share Information)

	Previous Fiscal Year (From April 1, 2015, to March 31, 2016)	Fiscal Year under Review (From April 1, 2016, to March 31, 2017)
Net assets per share	¥647.97	¥671.11
Profit per share	¥35.06	¥42.15

Notes: 1. Fully diluted profit per share is not presented since there were no potential shares.

2. The basis of calculation of net assets per share is as follows.

	Previous Fiscal Year (As of March 31, 2016)	Fiscal Year under Review (As of March 31, 2017)
Total net assets (¥ million)	156,148	165,920
Amount deducted from total net assets (¥ million)	25,762	30,877
(of which minority interests) (¥ million)	(25,762)	(30,877)
Net assets at term-end related to shares of common stock (¥ million)	130,386	135,043
Shares of common stock at term-end used to calculate net assets per share (1,000 shares)	201,224	201,224

3. The basis of calculation of net income per share and fully diluted net income per share is as follows.

	Previous Fiscal Year (From April 1, 2015, to March 31, 2016)	Fiscal Year under Review (From April 1, 2016, to March 31, 2017)
Net income attributable to owners of the parent (¥ million)	7,055	8,480
Amount not belonging to common shareholders (¥ million)	-	-
Net income related to shares of common stock (¥ million)	7,055	8,480
Average number of shares outstanding during the term (1,000 shares)	201,224	201,224

(Significant Subsequent Events)

(Issuance of unsecured bonds)

Based on the decision of the Board of Directors' meeting held March 21, 2017, the Company issued the following unsecured bonds.

The net proceeds are scheduled to fund redemption of bonds and working capital loans for subsidiaries.

	14th series of unsecured bonds (With inter-bond pari passu clause)	15th series of unsecured bonds (With inter-bond pari passu clause)	16th series of unsecured bonds (With inter-bond pari passu clause)
1. Total amount of issue	¥5.0 billion	¥5.0 billion	¥5.0 billion
2. Issue price	100% of the principal amount	100% of the principal amount	100% of the principal amount
3. Closing date	April 25, 2017	April 25, 2017	April 25, 2017
4. Maturity date	April 25, 2022	April 25, 2024	April 23, 2027
5. Coupon rate	0.100% per year	0.220% per year	0.315% per year

(Business combinations due to acquisitions)

(Acquisition of WaferGen Bio-systems, Inc.)

The Company's consolidated subsidiary Takara Bio Inc. concluded a merger agreement at the Board of Directors' meeting held on May 13, 2016 pursuant to which its wholly owned subsidiary Takara Bio USA Holdings Inc. ("TBUSH") will acquire the shares of WaferGen Bio-systems, Inc. ("WaferGen") and make it a subsidiary. On the same day, Japan time, TBUSH concluded this agreement with WaferGen. Furthermore, acquisition procedures were concluded per this agreement on February 28, 2017 (U.S. time).

(1) Outline of business combination

1) Name of the acquired company, name of the counterparty to the share acquisition, business contents and scale

Name of acquired company	WaferGen Bio-systems, Inc.	
Name of the counterparty to the share acquisition	Affiliates of Sabby Management, LLC and other shareholders	
Business	Manufacture and sale of research reagents and equipment	
Operating performance and financial position of the company for the fiscal year ended December 31, 2016	Capital:	123,716 thousand U.S. dollars
	Net assets:	49 thousand U.S. dollars
	Total assets:	10,980 thousand U.S. dollars
	Net sales:	10,733 thousand U.S. dollars
	Operating income:	(16,304) thousand U.S. dollars

2) Primary reasons for business combination

The Takara Bio Group provides research reagents, scientific instruments and contract research services for bio researchers. Particularly as regards Clontech brand products, focus has been placed on the development of reagent kits for next generation sequences out to widespread use in recent years, and reagent kits have been developed which use proprietary smart technology to specifically and efficiently amplify genes from extremely minute samples of RNA. Furthermore, recently the Takara Bio Group has also worked to develop reaction systems optimized for use with automatic analyzers with an eye towards use in the clinical domain.

Meanwhile, WaferGen offers equipment for analyzing single cells and reagent kits, as well as its proprietary qPCR minute multispecimen equipment to biotechnology companies, drug manufacturers, and clinical laboratories.

Strong synergistic effects are anticipated from the combination of single cell analysis and other WaferGen technologies with Takara Bio Group's molecular biology technology, including not only increased sales through equipment selling but also greater sales of reagent kits for single cell analysis among others.

3) Date of business combination

February 28, 2017 (U.S. time)

4) Legal form of business combination

Share acquisition

5) Name after business combination

WaferGen Bio-systems, Inc.

Note that the company is scheduled to be absorbed into Takara Bio USA, Inc., a wholly owned subsidiary of TBUSH, as of May 31, 2017 (U.S. time).

6) Percentage of voting rights acquired

100%

7) Primary basis for determining acquiring company

Cash acquisition of shares

(2) Cost of acquisition of company acquired and itemization of each type of compensation

Compensation Cash 35,908 thousand U.S. dollars

Cost of acquisition 35,908 thousand U.S. dollars

(3) Number of shares acquired and percentage of ownership after acquisition of shares
1) Number of shares owned before acquisition
0 shares
2) Number of shares acquired
Common stock: 3,798,112 shares (number of voting rights: 3,798,112)
3) Number of shares owned after acquisition of common stock
Common stock: 3,798,112 shares (number of voting rights: 3,798,112, ownership ratio of voting rights: 100%)

(4) Fund procurement and payment methods
The acquisition will be fully funded with Takara Bio Group's own funds.

(5) Contents and amounts of main acquisition costs
Advisory remuneration and handling charges, etc.: 3,682 thousand U.S. dollars

(6) Goodwill incurred, reason for the goodwill, and method and period of amortization
Yet to be determined as of the present time.

(7) Assets acquired and liabilities assumed on the date of business combination and major itemization of the same
Yet to be determined as of the present time.

(Acquisition of Rubicon Genomics, Inc.)

The Company's consolidated subsidiary Takara Bio Inc. made the decision at the Board of Directors' meeting held on December 15, 2016 pursuant to which TBUSH will acquire the shares of Rubicon Genomics, Inc. ("Rubicon") and make it a subsidiary. TBUSH acquired the relevant shares on January 17, 2017 (U.S. time).

(1) Outline of business combination
1) Name of the acquired company, name of the counterparty to the share acquisition, business contents and scale

Name of acquired company	Rubicon Genomics, Inc.	
Name of the counterparty to the share acquisition	Management and other shareholders of the company acquired	
Business	Manufacture and sale of research reagents and equipment	
Operating performance and financial position of the company for the fiscal year ended December 31, 2016	Capital:	13,249 thousand U.S. dollars
	Net assets:	1,397 thousand U.S. dollars
	Total assets:	4,940 thousand U.S. dollars
	Net sales:	12,554 thousand U.S. dollars
	Operating income:	2,127 thousand U.S. dollars

2) Primary reasons for business combination
Takara Bio Group has been focused on the development of next generation sequencing (NGS) reagent kits, which are used in a variety of fields ranging from basic research through industrial applications. By welcoming Rubicon into Takara Bio Group, Rubicon's sample preparation technologies for ultra-low input DNA sequencing analysis complement Takara Bio Group's sample preparation technologies for ultra-low input RNA sequencing analysis, allowing Takara Bio Group to provide a broader range of products and services in the area of ultra-low input nucleic acid analysis. Furthermore, with the addition of preparation systems (instruments) for NGS of WaferGen, Takara Bio Group will expand its products and services lineup across a wide range of area from basic research through industrial applications.

3) Date of business combination
January 17, 2017 (U.S. time)

4) Legal form of business combination

Share acquisition

5) Name after business combination
Rubicon Genomics, Inc.
Note that the company has been absorbed into Takara Bio USA, Inc., a wholly owned subsidiary of TBUSH, as of March 31, 2017 (U.S. time).

6) Percentage of voting rights acquired
100%

7) Primary basis for determining acquiring company
Cash acquisition of shares

(2) Cost of acquisition of company acquired and itemization of each type of compensation

Compensation	Cash	75,000 thousand U.S. dollars
Cost of acquisition		75,000 thousand U.S. dollars

(3) Number of shares acquired and percentage of ownership after acquisition of shares
1) Number of shares owned before acquisition
0 shares
2) Number of shares to be acquired
Common stock: 23,006,790 shares (number of voting rights: 23,006,790)
3) Number of shares owned after acquisition of common stock
Common stock: 23,006,790 shares (number of voting rights: 23,006,790, ownership ratio of voting rights: 100%)

(4) Fund procurement and payment methods
The acquisition will be fully funded with Takara Bio Group's own funds.

(5) Contents and amounts of main acquisition costs
Advisory remuneration and handling charges, etc.: 2,867 thousand U.S. dollars

(6) Goodwill incurred, reason for the goodwill, and method and period of amortization
Yet to be determined as of the present time.

(7) Assets acquired and liabilities assumed on the date of business combination and major itemization of the same
Yet to be determined as of the present time.

平成29年3月期
決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Year Ended March 31, 2017

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
   ① グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)
   ② 要約貸借対照表
   Consolidated Balance Sheets (Summary)

2. 宝酒造グループ
Takara Shuzo Group
   ① 要約損益計算書
   Statements of Income (Summary)
   ② 要約貸借対照表
   Balance Sheets (Summary)

3. タカラバイオグループ
Takara Bio Group
   ① 要約損益計算書
   Statements of Income (Summary)
   ② 要約貸借対照表
   Balance Sheets (Summary)

4. 平成29年3月期　参考資料
Reference Data for the Year Ended March 31, 2017

5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

6. 平成29年1月30日に発表した業績予想数値との比較
Change from forecast anounced Jan. 30, 2017

7. 平成30年3月期 業績予想
Financial forecast for the year ending March 31, 2018
   ① 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   ② 宝酒造
   Takara Shuzo Co.,Ltd.
   ③ 宝酒造インターナショナルグループ
   Takara Shuzo International Group
   ④ タカラバイオグループ
   Takara Bio Group

8. 平成30年3月期　参考資料
Reference Data for the year ending March 31, 2018

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

IR部 Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　IR部

Takara Holdings Inc. Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	平成28年3月期 FY2016	平成29年3月期 FY2017 / Apr. 1, 2016 - Mar. 31, 2017		対前期 Change from FY2016		対11/10予想 Change from forecast announced Nov. 2016	
	実績 Actual (a)	11/10予想 Forecast announced Nov. 10, 2016 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
宝酒造 グループ Takara Shuzo Group	192,025	201,600	201,171	9,146	104.8%	△ 428	99.8%
タカラバイオ グループ Takara Bio Group	29,729	28,600	29,375	△ 353	98.8%	775	102.7%
宝ヘルスケア Takara Healthcare Inc.	1,865	1,900	1,766	△ 99	94.7%	△ 133	93.0%
その他 Other, net	1,744	2,000	1,879	135	107.8%	△ 120	94.0%
売上高 Net sales	225,364	234,100	234,193	8,829	103.9%	93	100.0%
売上原価 Cost of sales	135,868	139,800	140,182	4,314	103.2%	382	100.3%
売上総利益 Gross profit	89,495	94,300	94,010	4,514	105.0%	△ 289	99.7%
運送費、保管料 Transportation and storage	8,682	9,000	8,743	60	100.7%	△ 256	97.2%
広告宣伝費 Advertising	3,365	3,300	3,198	△ 166	95.0%	△ 101	96.9%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	33,471	35,000	34,292	821	102.5%	△ 707	98.0%
研究開発費 Research and development	4,608	4,700	4,550	△ 58	98.7%	△ 149	96.8%
管理費、その他 Other, net	27,686	29,700	29,673	1,986	107.2%	△ 26	99.9%
販売費及び一般管理費 SG&A expenses	77,815	81,700	80,458	2,643	103.4%	△ 1,241	98.5%
宝酒造 グループ Takara Shuzo Group	8,410	9,200	9,755	1,345	116.0%	555	106.0%
タカラバイオ グループ Takara Bio Group	2,667	2,850	3,202	535	120.1%	352	112.4%
宝ヘルスケア Takara Healthcare Inc.	64	70	12	△ 51	19.7%	△ 57	18.2%
その他 Other, net	538	480	580	41	107.7%	100	120.9%
営業利益(△:損失) Operating income(Δ:loss)	11,680	＊ 12,600	13,551	1,870	116.0%	951	107.6%
受取利息・配当金 Interest and Dividends income	747	650	659	△ 87	88.2%	9	101.5%
その他営業外収益 Other, net	1,082	750	878	△ 204	81.1%	128	117.1%
営業外収益 Non-operating income	1,830	1,400	1,537	△ 292	84.0%	137	109.8%
支払利息 Interest and discounts expenses	447	550	481	34	107.7%	△ 68	87.6%
その他営業外費用 Other, net	223	150	262	39	117.6%	112	175.3%
営業外費用 Non-operating expenses	671	700	744	73	111.0%	44	106.4%
経常利益(△:損失) Ordinary income(Δ:loss)	12,840	＊ 13,300	14,344	1,504	111.7%	1,044	107.9%
特別利益 Extraordinary income	353	950	1,126	773	318.9%	176	118.6%
特別損失 Extraordinary loss	644	550	950	306	147.5%	400	172.9%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	12,548	13,700	14,520	1,971	115.7%	820	106.0%
法人税、住民税及び事業税 Current income taxes	4,839	4,800	5,208	369	107.6%	483	110.1%
法人税等調整額 Deferred income taxes	△ 60		74	135	—		
当期純利益(△:損失) Net income(Δ:loss)	7,769	8,900	9,236	1,466	118.9%	336	103.8%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	713	700	755	41	105.9%	55	108.0%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	7,055	＊ 8,200	8,480	1,425	120.2%	280	103.4%
設備投資額(有形・無形) Capital expenditures	6,003	6,638	6,658	654	110.9%	20	100.3%
減価償却費(有形・無形) Depreciation and Amortization	5,179	5,200	5,171	△ 8	99.8%	△ 28	99.5%
のれん償却額 Amortization of goodwill	538	460	586	47	108.8%	126	127.5%

＊ 営業利益、経常利益、親会社株主に帰属する当期純利益につきましては、平成29年3月期通期業績予想を1/30に修正しております。(p13参照)
The Company revised FY2017 forecasts concerning Operating income, Ordinary income and Net income attributable to owners of the parent on January 30, 2017. (c.f. p13.)

営業外収益 Non-operating income	受取利息193、受取配当金465、持分法による投資利益268、補助金収入288 など Interest income 193, Dividends income 465, Equity in earnings of affiliates 268, Subsidy income 288, etc.
営業外費用 Non-operating expenses	支払利息224、社債利息257 など Interest expense 224, Interest on bonds 257, etc.
特別利益 Extraordinary income	段階取得に係る差益878、固定資産売却益206 など Gain on step acquisitions 878, Gain on sales of noncurrent assets 206 etc.
特別損失 Extraordinary loss	減損損失667、固定資産除売却損264 など Impairment loss 667, Loss on sales and retirement of noncurrent assets 264, etc.

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets　　（百万円 :Millions of Yen）

	平成28年3月期末 As of Mar. 31, 2016	平成29年3月期末 As of Mar. 31, 2017	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	159,073	173,912	14,839	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	38,386	58,073	19,686	TH＋65.6、TS＋45.5、TB＋86.9
受取手形及び売掛金 Notes and accounts receivable-trade	53,602	57,951	4,349	TS＋38.2
有価証券 Marketable securities	28,238	13,237	△ 15,000	TH△70.0、TB△77.2
たな卸資産 Inventories	34,218	39,851	5,632	TS＋52.2
その他 Other current assets	4,859	5,035	175	
貸倒引当金 Allowance for doubtful accounts	△ 231	△ 236	△ 5	
（固定資産） (Total fixed assets)	94,179	100,456	6,276	
〔有形固定資産〕 [Property, plant and equipment]	53,065	59,174	6,108	
建物及び構築物 Buildings and structures	17,735	20,952	3,216	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	12,554	12,315	△ 239	新規取得 ＋66.5 （TS＋32.6、TB＋16.4） Newly purchases +66.5
土地 Land	18,118	20,089	1,970	減価償却 △51.7 （TS△31.9、TB△17.2） Depreciation Δ51.7
その他 Other property, plant and equipment	4,656	5,816	1,160	その他増減 ＋38.6 Other, net ＋38.6
〔無形固定資産〕 [Intangible fixed assets]	11,010	10,256	△ 754	
のれん Goodwill	6,975	6,626	△ 349	
その他 Other intangible fixed assets	4,035	3,630	△ 405	
〔投資その他の資産〕 [Investments and other assets]	30,103	31,025	922	
投資有価証券 Investment securities	24,747	25,583	835	TH＋37.9、TS△28.5
その他 Other assets	5,468	5,533	64	
貸倒引当金 Allowance for doubtful accounts	△ 112	△ 90	21	
資産合計 Total assets	253,253	274,368	21,115	

(TH=Takara Holdings Inc., TS=Takara Shuzo Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets　　（百万円 :Millions of Yen）

	平成28年3月期末 As of Mar. 31, 2016	平成29年3月期末 As of Mar. 31, 2017	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	47,648	65,506	17,858	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	15,201	16,804	1,603	TS＋14.1
短期借入金 Short-term loans payable	4,994	9,206	4,212	TS＋52.7
1年内償還の社債 Current portion of bonds	―	10,000	10,000	TH＋100.0 第9回普通社債(2017年9月償還)、第12回普通社債(2017年4月償還) #9SB (Redemption, Sept. 2017)、#12SB (Redemption, Apr. 2017)
未払酒税 Accrued alcohol tax	7,855	7,593	△ 261	
未払費用 Accrued expenses	4,965	5,562	597	TS＋8.6
販売促進引当金 Reserve for sales promotion expenses	1,870	1,899	29	
その他 Other current liabilities	12,760	14,439	1,678	
(固定負債) (Total non-current liabilities)	49,456	42,941	△ 6,514	
社債 Bonds payable	20,000	10,000	△ 10,000	TH△100.0 第9回普通社債(2017年9月償還)、第12回普通社債(2017年4月償還) #9SB (Redemption, Sept. 2017)、#12SB (Redemption, Apr. 2017)
長期借入金 Long-term loans payable	10,255	10,996	741	
退職給付に係る負債 Net defined benefit liability	8,544	8,961	416	
預り金 Deposits from customers	5,379	5,342	△ 36	
その他 Other non-current liabilities	5,277	7,640	2,362	
負債合計 Total liabilities	97,104	108,447	11,343	
資本金 Capital stock	13,226	13,226	―	
資本剰余金 Capital surplus	1,879	1,650	△ 229	
利益剰余金 Retained earnings	113,663	119,729	6,066	
自己株式 Treasury stock	△ 9,938	△ 9,939	△ 0	
(株主資本) (Total owner's equity)	118,830	124,667	5,836	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	6,822	9,583	2,760	TH＋26.2
繰延ヘッジ損益 Deffered gains or losses on hedges	△ 445	0	445	
為替換算調整勘定 Translation adjustments	5,548	1,426	△ 4,122	TS△34.6、TB△10.8 USD=116.53JPY, EUR=122.73JPY, GBP=143.06JPY (Dec. 2016) USD=120.54JPY, EUR=131.67JPY, GBP=178.60JPY (Dec. 2015)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 370	△ 634	△ 264	
(その他の包括利益累計額) (Total valuation and translation adjustments)	11,555	10,375	△ 1,179	
(非支配株主持分) (Noncontrolling interests)	25,762	30,877	5,115	TS＋51.4
純資産合計 Total net assets	156,148	165,920	9,771	
負債純資産合計 Total liabilities and net assets	253,253	274,368	21,115	

(TH=Takara Holdings Inc., TS=Takara Shuzo Group, TB=Takara Bio Group)

2. 宝酒造グループ :Takara Shuzo Group

① 要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成28年3月期 FY2016	平成29年3月期 FY2017 / Apr. 1, 2016 - Mar. 31, 2017		対前期 Change from FY2016		対11/10予想 Change from forecast anounced Nov. 2016	
	実績 Actual (a)	11/10予想 Forecast Nov. 10, 2016 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
焼酎 Shochu	59,376	59,300	58,001	△ 1,374	97.7%	△ 1,298	97.8%
清酒 Sake	24,736	25,200	24,822	85	100.3%	△ 377	98.5%
ソフトアルコール飲料 Light-alcohol refreshers	27,815	31,600	30,796	2,981	110.7%	△ 803	97.5%
その他酒類 Other liquors	14,170	14,000	14,116	△ 53	99.6%	116	100.8%
本みりん Hon Mirin	15,104	15,200	14,991	△ 113	99.2%	△ 208	98.6%
その他調味料 Other seasonings	9,314	9,700	9,749	435	104.7%	49	100.5%
原料用アルコール等 Raw alcohol	7,197	7,500	7,771	573	108.0%	271	103.6%
海外日本食材卸 Japanese food wholesale business in overseas markets	20,668	26,800	28,933	8,265	140.0%	2,133	108.0%
その他 Other	13,641	12,300	11,987	△ 1,653	87.9%	△ 312	97.5%
売上高 Net sales	192,025	201,600	201,171	9,146	104.8%	△ 428	99.8%
売上原価 Cost of sales	120,886	125,900	126,329	5,442	104.5%	429	100.3%
売上総利益 Gross profit	71,138	75,700	74,841	3,703	105.2%	△ 858	98.9%
運送費、保管料 Transportation and storage	7,924	8,300	8,019	95	101.2%	△ 280	96.6%
広告宣伝費 Advertising	2,824	2,700	2,723	△ 101	96.4%	23	100.9%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,405	34,000	33,337	931	102.9%	△ 662	98.1%
研究開発費 Research and development	329	400	344	15	104.7%	△ 55	86.1%
管理費、その他 Other, net	19,244	21,100	20,661	1,417	107.4%	△ 438	97.9%
販売費及び一般管理費 SG&A expenses	62,728	66,500	65,086	2,358	103.8%	△ 1,413	97.9%
営業利益（△：損失） Operating income(Δ:loss)	8,410	＊ 9,200	9,755	1,345	116.0%	555	106.0%
営業外収益 Non-operating income	757	600	601	△ 156	79.4%	1	100.2%
営業外費用 Non-operating expenses	441	400	410	△ 31	92.9%	10	102.6%
経常利益（△：損失） Ordinary income(Δ:loss)	8,726	＊ 9,400	9,946	1,220	114.0%	546	105.8%
特別利益 Extraordinary gain	85	800	925	839	1077.7%	125	115.7%
特別損失 Extraordinary loss	242	100	151	△ 91	62.3%	51	151.1%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	8,570	10,100	10,721	2,151	125.1%	621	106.2%
法人税、住民税及び事業税 Current income taxes	2,781	3,200	3,592	810	129.1%	394	112.3%
法人税等調整額 Deferred income taxes	124		2	△ 122	1.8%		
当期純利益（△：損失） Net income(Δ:loss)	5,663	6,900	7,126	1,463	125.8%	226	103.3%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	189	200	199	10	105.4%	△ 0	99.7%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	5,474	＊ 6,700	6,927	1,453	126.5%	227	103.4%

＊ 営業利益、経常利益、親会社株主に帰属する当期純利益につきましては、平成29年3月期通期業績予想を1/30に修正しております。(p13参照)
The Company revised FY2017 forecasts concerning Operating income, Ordinary income and Net income attributable to owners of the parent on January 30, 2017. (c.f. p13.)

設備投資額（有形・無形） Capital expenditures	2,919	2,952	3,269	349	112.0%	317	110.7%
減価償却費（有形・無形） Depreciation and Amortization	3,252	3,200	3,191	△ 60	98.1%	△ 8	99.7%
のれん償却額 Amortization of goodwill	357	280	424	66	118.6%	144	151.4%

② 要約貸借対照表 :Balance Sheets (Summary)

資産の部 :Assets

（百万円 :Millions of Yen）

	平成28年3月期末 As of Mar. 31, 2016	平成29年3月期末 As of Mar. 31, 2017	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	104,582	117,986	13,404	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	14,321	18,873	4,551	ﾐｭｰﾁｬﾙﾄﾚｰﾃﾞｨﾝｸﾞ＋32.1 Mutual Trading +32.1
受取手形及び売掛金 Notes and accounts receivable-trade	46,201	50,025	3,824	ﾐｭｰﾁｬﾙﾄﾚｰﾃﾞｨﾝｸﾞ＋33.9 Mutual Trading +33.9
有価証券 Marketable securities	10,516	10,237	△ 278	
たな卸資産 Inventories	28,962	34,184	5,221	ﾐｭｰﾁｬﾙﾄﾚｰﾃﾞｨﾝｸﾞ＋49.1 Mutual Trading +49.1
その他 Other current assets	4,769	4,870	101	
貸倒引当金 Allowance for doubtful accounts	△ 188	△ 204	△ 15	
（固定資産） (Total fixed assets)	46,191	48,711	2,519	
〔有形固定資産〕 [Property, plant and equipment]	27,990	33,829	5,838	
建物及び構築物 Buildings and structures	8,964	11,781	2,817	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	10,010	9,894	△ 116	新規取得 ＋32.6 Newly purchases +32.6
土地 Land	6,991	9,229	2,238	減価償却 △31.9 Depreciation Δ31.9
その他 Other property, plant and equipment	2,023	2,923	900	その他増減 ＋52.7 Other, net ＋52.7
〔無形固定資産〕 [Intangible fixed assets]	7,992	7,541	△ 451	
のれん Goodwill	5,334	5,412	78	
その他 Other intangible fixed assets	2,658	2,129	△ 529	
〔投資その他の資産〕 [Investments and other assets]	10,208	7,340	△ 2,867	
投資有価証券 Investment securities	6,393	3,541	△ 2,852	ﾐｭｰﾁｬﾙﾄﾚｰﾃﾞｨﾝｸﾞ社の連結子会社化による投資の消去 △3,052 Elimination of investment securities resulting from the conversion of Mutual Trading into a new consolidated subsidiary △3,052
その他 Other assets	3,872	3,842	△ 29	
貸倒引当金 Allowance for doubtful accounts	△ 58	△ 43	14	
資産合計 Total assets	150,773	166,697	15,924	

② 要約貸借対照表 :Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets　　（百万円 :Millions of Yen）

	平成28年3月期末 As of Mar. 31, 2016	平成29年3月期末 As of Mar. 31, 2017	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	40,948	48,687	7,739	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	12,300	13,719	1,419	ﾐｭｰﾁｬﾙﾄﾚｰﾃﾞｨﾝｸﾞ＋11.5 Mutual Trading +11.5
短期借入金 Short-term loans payable	5,642	10,918	5,276	ﾐｭｰﾁｬﾙﾄﾚｰﾃﾞｨﾝｸﾞ＋43.9、宝酒造 ＋10.0 Mutual Trading +43.9, Takara Shuzo +10.0
未払酒税 Accrued alcohol tax	7,855	7,593	△ 261	
未払費用 Accrued expenses	4,040	4,907	867	ﾐｭｰﾁｬﾙﾄﾚｰﾃﾞｨﾝｸﾞ＋7.4 Mutual Trading +7.4
販売促進引当金 Reserve for sales promotion expenses	1,870	1,899	29	
その他 Other current liabilities	9,238	9,648	409	
(固定負債) (Total non-current liabilities)	20,944	22,840	1,895	
長期借入金 Long-term loans payable	6,319	6,793	474	
退職給付に係る負債 Net defined benefit liability	7,601	7,870	268	
預り金 Deposits from customers	5,219	5,169	△ 50	
その他 Other non-current liabilities	1,804	3,006	1,202	
負債合計 Total liabilities	61,893	71,527	9,634	
資本金 Capital stock	1,000	1,000	―	
資本剰余金 Capital surplus	52,861	50,109	△ 2,752	宝酒造△25.2 Takara Shuzo △25.2
利益剰余金 Retained earnings	29,351	36,279	6,927	
(株主資本) (Total owner's equity)	83,213	87,388	4,175	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	435	567	132	
繰延ヘッジ損益 Deffered gains or losses on hedges	△ 445	0	445	
為替換算調整勘定 Translation adjustments	3,654	193	△ 3,460	Exchange Rate USD=116.53JPY, EUR=122.73JPY, GBP=143.06JPY (Dec. 2016) USD=120.54JPY, EUR=131.67JPY, GBP=178.60JPY (Dec. 2015)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 217	△ 361	△ 144	
(その他の包括利益累計額) (Total valuation and translation adjustments)	3,427	400	△ 3,026	
(非支配株主持分) (Noncontrolling interests)	2,239	7,380	5,141	ﾐｭｰﾁｬﾙﾄﾚｰﾃﾞｨﾝｸﾞ＋41.3 Mutual Trading +41.3
純資産合計 Total net assets	88,880	95,170	6,289	
負債純資産合計 Total liabilities and net assets	150,773	166,697	15,924	

3. タカラバイオグループ :Takara Bio Group

① 要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成28年3月期 FY2016	平成29年3月期 FY2017 / Apr. 1, 2016 - Mar. 31, 2017		対前期 Change from FY2016		対11/10予想 Change from forecast anounced Nov. 2016	
	実績 Actual (a)	11/10予想 Forecast Nov. 19, 2016 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
研究用試薬 Research reagents	20,488	19,515	19,436	△ 1,051	94.9%	△ 78	99.6%
理化学機器 Scientific instruments	3,087	2,663	2,911	△ 176	94.3%	247	109.3%
受託・その他 Contracted service and other	3,744	4,015	4,225	480	112.8%	209	105.2%
バイオ産業支援　計 Bioindustry	27,320	26,195	26,573	△ 747	97.3%	378	101.4%
遺伝子医療 Gene Therapy	—	—	500	500	—	500	—
医食品バイオ AgriBio	2,408	2,404	2,301	△ 106	95.6%	△ 102	95.7%
売上高 Net sales	29,729	＊ 28,600	29,375	△ 353	98.8%	775	102.7%
売上原価 Cost of sales	13,405	12,061	12,422	△ 983	92.7%	360	103.0%
売上総利益 Gross profit	16,323	16,538	16,952	629	103.9%	414	102.5%
運送費、保管料 Transportation and storage	632	584	594	△ 37	94.1%	10	101.9%
広告宣伝費 Advertising	122	102	89	△ 33	72.6%	△ 13	87.1%
販売促進費 Sales promotion	971	901	854	△ 117	87.9%	△ 47	94.7%
研究開発費 Research and development	4,275	4,275	4,101	△ 174	95.9%	△ 174	95.9%
管理費、その他 Other, net	7,654	7,824	8,110	456	106.0%	286	103.7%
販売費及び一般管理費 SG&A expenses	13,655	13,688	13,749	93	100.7%	61	100.5%
バイオ産業支援 Bioindustry	6,138	6,476	6,218	79	101.3%	△ 258	96.0%
遺伝子医療 Gene Therapy	△ 1,773	△ 2,049	△ 1,380	393	—	669	—
医食品バイオ AgriBio	110	160	104	△ 6	94.1%	△ 55	65.1%
共通 Eliminations/Corporate	△ 1,808	△ 1,737	△ 1,739	69	—	△ 1	—
営業利益（△：損失） Operating income(Δ:loss)	2,667	＊ 2,850	3,202	535	120.1%	352	112.4%
営業外収益 Non-operating income	642	375	445	△ 196	69.4%	69	118.6%
営業外費用 Non-operating expenses	8	75	68	60	852.4%	△ 6	91.3%
経常利益（△：損失） Ordinary income(Δ:loss)	3,301	＊ 3,150	3,579	277	108.4%	429	113.6%
特別利益 Extraordinary income	4	2	2	△ 1	62.5%	0	102.2%
特別損失 Extraordinary loss	399	380	775	376	194.2%	395	203.9%
税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss)	2,905	2,771	2,805	△ 99	96.6%	33	101.2%
法人税、住民税及び事業税 Current income taxes	1,653	1,417	1,492	△ 160	90.3%	31	102.2%
法人税等調整額 Deferred income taxes	△ 88		△ 43	44	—		
当期純利益（△：損失） Net income(Δ:loss)	1,340	1,353	1,356	16	101.2%	2	100.2%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	5	3	3	△ 2	59.4%	△ 0	83.1%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	1,334	1,350	1,352	18	101.4%	2	100.2%

＊ 売上高、営業利益、経常利益につきましては、平成29年3月期通期業績予想を1/30に修正しております。(p13参照)
The Company revised FY2017 forecasts concerning Net sales, Operating income and Ordinary income on January 30, 2017. (c.f. p13.)

設備投資額（有形・無形） Capital expenditures	2,090	2,200	1,648	△ 441	78.9%	△ 551	74.9%
減価償却費（有形・無形） Depreciation and Amortization	1,687	1,753	1,722	34	102.0%	△ 31	98.2%
のれん償却額 Amortization of goodwill	181	159	162	△ 18	89.6%	3	102.0%

② 要約貸借対照表 :Balance Sheets (Summary)

資産の部 :Assets　　（百万円 :Millions of Yen）

	平成28年3月期末 As of Mar. 31, 2016	平成29年3月期末 As of Mar. 31, 2017	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	42,158	43,964	1,806	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	19,384	28,078	8,693	ﾀｶﾗﾊﾞｲｵUSAﾎｰﾙﾃﾞｨﾝｸﾞｽ 139.2、タカラバイオ△57.4 Takara Bio USA Holdings +139.2, Takara Bio △57.4
受取手形及び売掛金 Notes and accounts receivable-trade	6,830	7,455	625	
有価証券 Marketable securities	9,721	2,000	△ 7,721	タカラバイオ△69.9 Takara Bio △69.9
たな卸資産 Inventories	5,100	5,462	362	
その他 Other current assets	1,163	998	△ 164	
貸倒引当金 Allowance for doubtful accounts	△ 41	△ 30	11	
（固定資産） (Total fixed assets)	24,432	23,178	△ 1,254	
〔有形固定資産〕 [Property, plant and equipment]	20,534	19,577	△ 957	
建物及び構築物 Buildings and structures	8,207	7,667	△ 540	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	2,461	2,349	△ 111	新規取得　＋16.4 Newly purchases +16.4
土地 Land	7,696	7,297	△ 398	減価償却　△17.2 Depreciation Δ17.2
その他 Other property, plant and equipment	2,170	2,263	93	その他増減　△12.7 Other, net △12.7
〔無形固定資産〕 [Intangible fixed assets]	2,695	2,301	△ 394	
のれん Goodwill	1,641	1,213	△ 427	
その他 Other intangible fixed assets	1,054	1,087	33	
〔投資その他の資産〕 [Investments and other assets]	1,202	1,299	97	
長期前払費用 Long-term prepaid expenses	1,021	856	△ 165	
その他 Other assets	192	454	262	
貸倒引当金 Allowance for doubtful accounts	△ 11	△ 11	－	
資産合計 Total assets	66,591	67,143	552	

② 要約貸借対照表 :Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets　　（百万円 :Millions of Yen）

	平成28年3月期末 As of Mar. 31, 2016	平成29年3月期末 As of Mar. 31, 2017	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	5,430	6,025	595	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	1,690	1,944	253	
短期借入金 Short-term loans payable	63	47	△ 16	
その他 Other current liabilities	3,675	4,033	358	
(固定負債) (Total non-current liabilities)	1,050	1,131	81	
長期借入金 Long-term loans payable	130	82	△ 47	
退職給付に係る負債 Net defined benefit liability	488	622	134	
その他 Other non-current liabilities	431	426	△ 5	
負債合計 Total liabilities	6,480	7,157	677	
資本金 Capital stock	14,965	14,965	―	
資本剰余金 Capital surplus	32,893	32,893	―	
利益剰余金 Retained earnings	9,295	10,432	1,136	
(株主資本) (Total owner's equity)	57,155	58,291	1,136	
為替換算調整勘定 Translation adjustments	3,109	2,023	△ 1,086	Exchange Rate USD=116.53JPY, EUR=122.73JPY, GBP=143.06JPY (Dec. 2016) USD=120.54JPY, EUR=131.67JPY, GBP=178.60JPY (Dec. 2015)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 257	△ 429	△ 172	
(その他の包括利益累計額) (Total valuation and translation adjustments)	2,852	1,593	△ 1,258	
(非支配株主持分) (Noncontrolling interests)	102	100	△ 2	
純資産合計 Total net assets	60,110	59,985	△ 124	
負債純資産合計 Total liabilities and net assets	66,591	67,143	552	

4. 平成29年3月期 参考資料 :Reference Data for the Year Ended March 31, 2017

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成28年3月期 FY2016	平成29年3月期 FY2017 / Apr. 1, 2016 - Mar. 31, 2017			
	実績 Actual (a)	11/10予想 Forecast announced Nov. 10, 2016 (b)	実績 Actual (c)	前期差 Change(c-a)	予想差 Difference(c-b)
米ドル : US dollar	121.11	106.40	108.81	△ 12.30	2.41
ポンド: Pound	185.20	146.10	147.64	△ 37.56	1.54
ユーロ: Euro	134.31	118.60	120.30	△ 14.01	1.70
人民元: Yuan	19.23	16.10	16.36	△ 2.87	0.26
100ウォン: 100 Won	10.71	9.10	9.37	△ 1.34	0.27
インドルピー: Rupee	1.89	1.59	1.62	△ 0.27	0.03
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	14.36	12.60	12.72	△ 1.64	0.12
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	88.25	77.70	78.76	△ 9.49	1.06

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2016	対11/10予想 Change from forecast announced Nov. 2016
焼酎 Shochu	△ 23	3
清酒 Sake	△ 284	48
ソフトアルコール飲料 Light-alcohol refreshers	△ 4	0
その他酒類 Other liquors	△ 827	81
本みりん Hon Mirin	△ 58	8
その他調味料 Other seasonings	△ 46	7
原料用アルコール等 Raw alcohol	—	—
海外日本食材卸 Japanese food wholesale business in overseas markets	△ 3,132	951
その他 Other	—	—
宝酒造グループ 計 Net sales of Takara Shuzo Group	△ 4,377	1,100
研究用試薬 Research reagents	△ 1,854	263
理化学機器 Scientific instruments	△ 17	2
受託・その他 Contracted service and other	△ 138	16
バイオ産業支援 計 Bioindustry	△ 2,010	282
遺伝子医療 Gene Therapy	—	—
医食品バイオ AgriBio	—	—
タカラバイオグループ 計 Net sales of Takara Bio Group	△ 2,010	282
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	△ 6,388	1,383

② 海外売上高比率の推移 :Change in overseas sales ratio

	平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017
宝酒造グループ Takara Shuzo Group	5.8%	8.9%	13.7%	15.7%	18.5%
タカラバイオグループ Takara Bio Group	39.1%	45.9%	50.3%	54.2%	50.4%
その他 Other	0.0%	—	0.0%	-	-
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	9.1%	13.0%	17.8%	20.5%	22.2%

③ 海外主要子会社の業績 :Financial Result of major overseas subsidiaries

		平成28年3月期 実績 FY2016 Actual		平成29年3月期 実績 FY2017 Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	31,052	3,676	32,782	4,750
Takara Sake USA Inc.	百 万 円 :Millions of Yen	3,760	445	3,567	516
宝酒造食品	千 元 :Thousands of Yuan	48,326	3,262	46,997	2,404
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	929	62	768	39
トマーチン	千 ポ ン ド :Thousands of Pound	15,576	3,091	14,509	3,364
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	2,884	572	2,142	496
エイジ・インターナショナル	千 US ドル :Thousands of US dollar	17,173	6,256	20,479	7,774
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	2,079	757	2,228	845
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	113,473	12,009	133,913	15,764
FOODEX Group	百 万 円 :Millions of Yen	15,240	1,612	16,109	1,896
タザキフーズ	千 ポ ン ド :Thousands of Pound	29,513	2,868	34,481	1,995
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	5,465	531	5,090	294
タカラバイオヨーロッパS.A.S.	千 ユ ー ロ :Thousands of Euro	17,314	2,121	19,372	2,299
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	2,325	284	2,330	276
タカラバイオヨーロッパAB	千 SEK :Thousands of Sweden Krona	27,314	Δ 16,576	28,009	Δ 15,329
Takara Bio Europe AB	百 万 円 :Millions of Yen	392	Δ 238	356	Δ 194
宝生物工程(大連)	千 元 :Thousands of Yuan	291,253	125,143	305,664	124,340
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	5,600	2,406	5,000	2,034
宝日医生物技術(北京)	千 元 :Thousands of Yuan	96,756	Δ 1,650	135,179	3,737
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	1,860	Δ 31	2,211	61
タカラコリアバイオメディカル	百 万 ウ ォ ン :Millions of Won	8,601	999	8,921	1,250
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	921	107	835	117
タカラバイオDSSインド	千インドルピー :Thousands of Rupee	187,515	766	196,570	Δ 581
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	354	1	318	Δ 0
タカラバイオUSA	千 US ドル :Thousands of US dollar	67,962	11,996	75,697	16,996
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	8,230	1,452	8,236	1,849

④ 宝酒造グループ 営業利益増減要因 :Factors of change in operating income of Takara Shuzo Group

(百万円 :Millions of Yen)

要因 Factors	対前期増減 Change from FY2016	内容 Detail	対11/10予想増減 Change from forecast announced Nov. 2016	内容 Detail
売上総利益の増減 (宝酒造単体) Change in Gross profit of TAKARA SHUZO CO.,LTD.	+2,240	数量差+1,665 単価差 +574 Change in quantities +1,665 Change in unit price +574 ➢主な内訳 Breakdown 焼酎△179(数量差△581 単価差+402) Shochu △179 (Change in quantities △581 Change in unit price +402) 清酒+177(数量差+327 単価差△149) Sake +177 (Change in quantities +327 Change in unit price △149) ソフアル+1,566(数量差+1,394 単価差+172) Light-alcohol refreshers +1,566(Change in quantities +1,394 Change in unit price +172) 本みりん+113(数量差+2 単価差+111) Hon Mirin+113 (Change in quantities +2 Change in unit price +111) (参考)原価コストダウン +417 Reference :Cost reduction +417 ※上記数量差および単価差に含む *Included in changes above	Δ 1,530	数量差 △166 単価差 △1,364 Change in quantities △166 Change in unit price △1,364 (参考)原価コストダウン △202 Reference :Cost reduction △202 ※上記数量差および単価差に含む *Included in changes above
販売費及び一般管理費の増減 (宝酒造単体) Change in SG&A expenses of TAKARA SHUZO CO.,LTD.	Δ 1,236	運送費の増加 △302 Change in Transportation △302 広告宣伝費の減少 +72 Change in Advertising +72 販売促進費の増加 △984 Change in Sales promotion and allowance for s.p. △984	+1,398	運送費の減少 +79 Change in Transportation +79 広告宣伝費の減少 +40 Change in Advertising +40 販売促進費の減少 +558 Change in Sales promotion and allowance for s.p. +558
宝酒造単体 計 TAKARA SHUZO CO.,LTD.	+1,003		Δ 132	
その他の子会社における 営業利益の増減 Change in Operating income of other subsidiaries	+341	海外日本食材卸会社 +369 ※のれん償却後 (フーデックスグループ +303、タザキフーズ △196 ミューチャルトレーディング +263) Japanese food wholesale business in overseas markets +369 Foodex Group +303 TAZAKI FOODS LTD. △196 Mutual Trading +263 *Include amortization of goodwill その他の海外子会社 +63 Other overseas subsidiaries +63 国内子会社 +76 Domestic subsidiaries +76 連結消去等 △168 Elimination of intra-company transactions,etc. △168	+688	海外日本食材卸会社 +149 ※のれん償却後 (フーデックスグループ +123、タザキフーズ △0) ミューチャルトレーディング +26) Japanese food wholesale business in overseas markets +149 Foodex Group +123 TAZAKI FOODS LTD. △0 Mutual Trading +26 *Include amortization of goodwill その他の海外子会社 +322 Other overseas subsidiaries +322 国内子会社 +79 Domestic subsidiaries +79 連結消去等 +136 Elimination of intra-company transactions,etc. +136
宝酒造グループ 計 Takara Shuzo Group	+1,345		+555	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

5. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成24年3月期 FY2012	平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	前期対比 Change from FY2016 増減 Change	前期対比 Change from FY2016 比 YOY%
売上高	Net sales	198,690	200,989	209,568	219,490	225,364	234,193	8,829	103.9%
売上原価	Cost of sales	121,462	123,630	129,447	134,390	135,868	140,182	4,314	103.2%
（売上高原価率）	(Ratio to Net sales)	61.1%	61.5%	61.8%	61.2%	60.3%	59.9%	-0.4pt	–
売上総利益	Gross profit	77,228	77,359	80,121	85,099	89,495	94,010	4,514	105.0%
販売費及び一般管理費	SG&A expenses	67,963	68,225	70,631	74,003	77,815	80,458	2,643	103.4%
（売上高販管費率）	(Ratio to Net sales)	34.2%	33.9%	33.7%	33.7%	34.5%	34.4%	-0.2pt	–
営業利益（△:損失）	Operating income(Δ:loss)	9,264	9,133	9,490	11,096	11,680	13,551	1,870	116.0%
（売上高営業利益率）	(Ratio to Net Sales)	4.7%	4.5%	4.5%	5.1%	5.2%	5.8%	+0.6pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	32,436	32,838	32,954	32,818	33,471	34,292	821	102.5%
（売上高販促費率）	(Ratio to Net sales)	16.3%	16.3%	15.7%	15.0%	14.9%	14.6%	-0.2pt	–
研究開発費	R&D expenses	3,027	3,090	3,376	3,754	4,608	4,550	Δ 58	98.7%
（売上高研究開発費率）	(Ratio to Net sales)	1.5%	1.5%	1.6%	1.7%	2.0%	1.9%	-0.1pt	–
設備投資額（有形・無形）	Capital expenditures	5,330	5,282	8,967	9,533	6,003	6,658	654	110.9%
減価償却費（有形・無形）	Depreciation and Amortization	4,431	4,251	4,287	4,662	5,179	5,171	Δ 8	99.8%
のれん償却額	Amortization of goodwill	271	267	348	500	538	586	47	108.8%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成24年3月期 FY2012	平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	前期対比 Change from FY2016 増減 Change	前期対比 Change from FY2016 比 YOY%
売上高	Net sales	175,503	176,946	182,306	190,089	192,025	201,171	9,146	104.8%
売上原価	Cost of sales	110,454	112,384	116,619	120,691	120,886	126,329	5,442	104.5%
（売上高原価率）	(Ratio to Net sales)	62.9%	63.5%	64.0%	63.5%	63.0%	62.8%	-0.2pt	–
売上総利益	Gross profit	65,049	64,562	65,686	69,397	71,138	74,841	3,703	105.2%
販売費及び一般管理費	SG&A expenses	58,280	58,174	59,357	61,556	62,728	65,086	2,358	103.8%
（売上高販管費率）	(Ratio to Net sales)	33.2%	32.9%	32.6%	32.4%	32.7%	32.4%	-0.3pt	–
営業利益（△:損失）	Operating income(Δ:loss)	6,768	6,387	6,329	7,840	8,410	9,755	1,345	116.0%
（売上高営業利益率）	(Ratio to Net sales)	3.9%	3.6%	3.5%	4.1%	4.4%	4.8%	+0.5pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	31,433	31,815	31,889	31,818	32,405	33,337	931	102.9%
（売上高販促費率）	(Ratio to Net sales)	17.9%	18.0%	17.5%	16.7%	16.9%	16.6%	-0.3pt	–
設備投資額（有形・無形）	Capital expenditures	2,743	2,529	2,954	4,594	2,919	3,269	349	112.0%
減価償却費（有形・無形）	Depreciation and Amortization	3,225	2,997	2,968	3,170	3,252	3,191	Δ 60	98.1%
のれん償却額	Amortization of goodwill	146	148	217	363	357	424	66	118.6%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成24年3月期 FY2012	平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	前期対比 Change from FY2016 増減 Change	前期対比 Change from FY2016 比 YOY%
売上高	Net sales	19,578	20,564	23,905	25,969	29,729	29,375	Δ 353	98.8%
売上原価	Cost of sales	9,194	9,540	11,331	12,142	13,405	12,422	Δ 983	92.7%
（売上高原価率）	(Ratio to Net sales)	47.0%	46.4%	47.4%	46.8%	45.1%	42.3%	-2.8pt	–
売上総利益	Gross profit	10,383	11,024	12,574	13,827	16,323	16,952	629	103.9%
販売費及び一般管理費	SG&A expenses	8,836	9,332	10,619	11,524	13,655	13,749	93	100.7%
（売上高販管費率）	(Ratio to Net sales)	45.1%	45.4%	44.4%	44.4%	45.9%	46.8%	+0.9pt	–
営業利益（△:損失）	Operating income(Δ:loss)	1,547	1,691	1,954	2,302	2,667	3,202	535	120.1%
（売上高営業利益率）	(Ratio to Net sales)	7.9%	8.2%	8.2%	8.9%	9.0%	10.9%	+1.9pt	–
研究開発費	R&D expenses	2,658	2,715	3,026	3,401	4,275	4,101	Δ 174	95.9%
（売上高研究開発費率）	(Ratio to Net sales)	13.6%	13.2%	12.7%	13.1%	14.4%	14.0%	-0.4pt	–
設備投資額（有形・無形）	Capital expenditures	926	2,397	5,538	4,762	2,090	1,648	Δ 441	78.9%
減価償却費（有形・無形）	Depreciation and Amortization	1,077	1,104	1,157	1,347	1,687	1,722	34	102.0%
のれん償却額	Amortization of goodwill	124	119	131	136	181	162	Δ 18	89.6%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成24年3月期 FY2012	平成25年3月期 FY2013	平成26年3月期 FY2014	平成27年3月期 FY2015	平成28年3月期 FY2016	平成29年3月期 FY2017	前期対比 Change from FY2016 増減 Change	前期対比 Change from FY2016 比 YOY%
売上高	Net sales	2,338	2,008	1,424	1,652	1,865	1,766	Δ 99	94.7%
売上原価	Cost of sales	1,492	1,233	674	803	893	669	Δ 223	74.9%
（売上高原価率）	(Ratio to Net sales)	63.8%	61.4%	47.4%	48.6%	47.9%	37.9%	-10.0pt	–
売上総利益	Gross profit	845	774	749	848	972	1,097	124	112.8%
販売費及び一般管理費	SG&A expenses	960	797	728	810	907	1,084	176	119.5%
（売上高販管費率）	(Ratio to Net sales)	41.1%	39.7%	51.1%	49.1%	48.6%	61.4%	+12.7pt	–
営業利益（△:損失）	Operating income(Δ:loss)	Δ 114	Δ 22	21	38	64	12	Δ 51	19.7%
（売上高営業利益率）	(Ratio to Net sales)	–	–	1.5%	2.3%	3.5%	0.7%	-2.7pt	–
ヘルスケア事業売上高	Net sales of Healthcare products	1,220	1,265	1,424	1,652	1,865	1,766	Δ 99	94.7%
設備投資額（有形・無形）	Capital expenditures	32	1	5	9	5	12	6	218.6%
減価償却費（有形・無形）	Depreciation and Amortization	12	10	0	1	3	4	1	136.0%

6. 平成29年1月30日に発表した業績予想数値との比較 :Change from forecast anounced Jan. 30, 2017

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	平成28年3月期 FY2016	平成29年3月期 FY2017 / Apr. 1, 2016 - Mar. 31, 2017		対前期 Change from FY2016		対1/30予想 Change from forecast anounced Jan. 2017	
	実績 Actual (a)	1/30予想 Forecast announced Jan. 30, 2017 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
売上高 Net sales	225,364	234,100	234,193	8,829	103.9%	93	100.0%
営業利益(△:損失) Operating income(Δ:loss)	11,680	13,100	13,551	1,870	116.0%	451	103.4%
経常利益(△:損失) Ordinary income(Δ:loss)	12,840	13,800	14,344	1,504	111.7%	544	103.9%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	7,055	8,300	8,480	1,425	120.2%	180	102.2%

宝酒造グループ :Takara Shuzo Group

(百万円 :Millions of Yen)

	平成28年3月期 FY2016	平成29年3月期 FY2017 / Apr. 1, 2016 - Mar. 31, 2017		対前期 Change from FY2016		対1/30予想 Change from forecast anounced Jan. 2017	
	実績 Actual (a)	1/30予想 Forecast announced Jan. 30, 2017 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
売上高 Net sales	192,025	201,600	201,171	9,146	104.8%	△ 428	99.8%
営業利益(△:損失) Operating income(Δ:loss)	8,410	9,400	9,755	1,345	116.0%	355	103.8%
経常利益(△:損失) Ordinary income(Δ:loss)	8,726	9,600	9,946	1,220	114.0%	346	103.6%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	5,474	6,800	6,927	1,453	126.5%	127	101.9%

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	平成28年3月期 FY2016	平成29年3月期 FY2017 / Apr. 1, 2016 - Mar. 31, 2017		対前期 Change from FY2016		対1/30予想 Change from forecast anounced Jan. 2017	
	実績 Actual (a)	1/30予想 Forecast announced Jan. 30, 2017 (b)	実績 Actual (c)	増減 Change (c-a)	比 % (c/a)	増減 Difference (c-b)	比 % (c/b)
売上高 Net sales	29,729	29,100	29,375	△ 353	98.8%	275	100.9%
営業利益(△:損失) Operating income(Δ:loss)	2,667	3,100	3,202	535	120.1%	102	103.3%
経常利益(△:損失) Ordinary income(Δ:loss)	3,301	3,430	3,579	277	108.4%	149	104.4%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	1,334	1,350	1,352	18	101.4%	2	100.2%

7. 平成30年3月期 業績予想 :Financial forecast for the year ending March 31, 2018

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	平成29年3月期 通期 実績 FY2017 Actual (a)	平成30年3月期 通期 予想 FY2018 Forecast (b)	対前期 Change from FY2017 増減 Change (b-a)	対前期 Change from FY2017 比 % (b/a)	平成29年3月期 第2四半期累計 実績 FY2017(1Q-2Q) Actual (c)	平成30年3月期 第2四半期累計 予想 FY2018(1Q-2Q) Forecast (d)	対前期 Change from FY2017(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2017(1Q-2Q) 比 % (d/c)
宝酒造 Takara Shuzo Group	149,452	153,000	3,547	102.4%	70,429	71,000	570	100.8%
宝酒造インターナショナルグループ Takara Shuzo International Group	37,540	63,000	25,459	167.8%	15,137	31,000	15,862	204.8%
タカラバイオ グループ Takara Bio Group	29,375	33,200	3,824	113.0%	13,199	14,049	849	106.4%
その他 Other	39,017	39,000	△ 17	100.0%	18,648	19,000	351	101.9%
調整額 Adjustment	△ 21,193	△ 20,200	993	—	△ 9,905	△ 10,049	△ 143	—
売上高 Net sales	234,193	268,000	33,806	114.4%	107,509	125,000	17,490	116.3%
売上原価 Cost of sales	140,182	163,000	22,817	116.3%	64,073	77,000	12,926	120.2%
売上総利益 Gross profit	94,010	105,000	10,989	111.7%	43,435	48,000	4,564	110.5%
運送費、保管料 Transportation and storage	8,743	9,600	856	109.8%	4,269	4,600	330	107.7%
広告宣伝費 Advertising	3,198	3,300	101	103.2%	1,505	1,600	94	106.3%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	34,292	35,400	1,107	103.2%	16,382	16,800	417	102.5%
研究開発費 Research and development	4,550	5,300	749	116.5%	2,093	2,400	306	114.6%
管理費、その他 Other, net	29,673	37,400	7,726	126.0%	13,977	17,900	3,922	128.1%
販売費及び一般管理費 SG&A expenses	80,458	91,000	10,541	113.1%	38,228	43,300	5,071	113.3%
宝酒造 Takara Shuzo Group	5,071	5,600	528	110.4%	1,451	1,500	48	103.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	3,182	3,700	517	116.2%	1,393	1,800	406	129.2%
タカラバイオ グループ Takara Bio Group	3,202	3,300	97	103.0%	1,377	487	△ 889	35.4%
その他 Other	2,167	2,300	132	106.1%	976	1,000	23	102.4%
調整額 Adjustment	△ 72	△ 900	△ 827	—	8	△ 87	△ 95	—
営業利益(△:損失) Operating income(Δ:loss)	13,551	14,000	448	103.3%	5,207	4,700	△ 507	90.3%
受取利息・配当金 Interest and Dividends income	659	600	△ 59	91.0%	364	300	△ 64	82.3%
その他営業外収益 Other, net	878	600	△ 278	68.3%	366	200	△ 166	54.6%
営業外収益 Non-operating income	1,537	1,200	△ 337	78.0%	731	500	△ 231	68.4%
支払利息 Interest and discounts expenses	481	600	118	124.5%	213	300	86	140.4%
その他営業外費用 Other, net	262	200	△ 62	76.1%	110	200	89	180.5%
営業外費用 Non-operating expenses	744	800	55	107.4%	324	500	175	154.1%
経常利益(△:損失) Ordinary income(Δ:loss)	14,344	14,400	55	100.4%	5,614	4,700	△ 914	83.7%
特別利益 Extraordinary gain	1,126	1,400	273	124.3%	21	—	△ 21	—
特別損失 Extraordinary loss	950	600	△ 350	63.1%	60	100	39	166.3%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	14,520	15,200	679	104.7%	5,575	4,600	△ 975	82.5%
法人税、住民税及び事業税 Current income taxes	5,208	5,500	216	104.1%	2,321	2,000	△ 82	96.0%
法人税等調整額 Deferred income taxes	74				△ 239			
当期純利益(△:損失) Net income(Δ:loss)	9,236	9,700	463	105.0%	3,492	2,600	△ 892	74.4%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	755	1,200	444	158.8%	315	200	△ 115	63.4%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent	8,480	8,500	19	100.2%	3,177	2,400	△ 777	75.5%
設備投資額(有形・無形) Capital expenditures	6,658	7,051	392	105.9%	1,909			
減価償却費(有形・無形) Depreciation and Amortization	5,171	6,600	1,428	127.6%	2,492	3,100	607	124.4%
のれん償却額 Amortization of goodwill	586	920	333	156.9%	238	440	201	184.7%

(注)平成29年3月期通期実績の売上高およびセグメント別損益(営業利益)は、平成30年3月期からの新セグメントに従って組み替えて表示しております。

② 宝酒造 :Takara Shuzo Co., Ltd.

（百万円 :Millions of Yen）

	平成29年3月期 通期 実績 FY2017 Actual (a)	平成30年3月期 通期 予想 FY2018 Forecast (b)	対前期 Change from FY2017 増減 Change (b-a)	対前期 Change from FY2017 比 % (b/a)	平成29年3月期 第2四半期累計 実績 FY2017(1Q-2Q) Actual (c)	平成30年3月期 第2四半期累計 予想 FY2018(1Q-2Q) Forecast (d)	対前期 Change from FY2017(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2017(1Q-2Q) 比 % (d/c)
焼酎 Shochu	57,783	56,100	△ 1,683	97.1%	28,261	27,000	△ 1,261	95.5%
清酒 Sake	22,387	23,500	1,112	105.0%	8,353	8,800	446	105.3%
ソフトアルコール飲料 Light-alcohol refreshers	30,721	34,500	3,778	112.3%	15,614	17,000	1,385	108.9%
その他酒類 Other liquors	6,898	6,800	△ 98	98.6%	3,463	3,400	△ 63	98.2%
本みりん Hon Mirin	14,506	14,700	193	101.3%	6,822	6,800	△ 22	99.7%
その他調味料 Other seasonings	9,383	10,000	616	106.6%	4,454	4,700	245	105.5%
原料用アルコール等 Raw alcohol	7,771	7,400	△ 371	95.2%	3,460	3,300	△ 160	95.4%
売上高 Net sales	149,452	153,000	3,547	102.4%	70,429	71,000	570	100.8%
売上原価 Cost of sales	89,278	90,800	1,521	101.7%	42,478	42,700	221	100.5%
売上総利益 Gross profit	60,174	62,200	2,025	103.4%	27,950	28,300	349	101.2%
運送費、保管料 Transportation and storage	7,106	7,400	293	104.1%	3,339	3,400	60	101.8%
広告宣伝費 Advertising	2,637	2,700	62	102.4%	1,211	1,300	88	107.3%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,923	33,900	976	103.0%	15,754	15,900	145	100.9%
研究開発費 Research and development	345	400	54	115.8%	170	200	29	117.1%
管理費、その他 Other, net	12,090	12,200	109	100.9%	6,022	6,000	△ 22	99.6%
販売費及び一般管理費 SG&A expenses	55,103	56,600	1,496	102.7%	26,499	26,800	300	101.1%
営業利益（△：損失） Operating income(Δ:loss)	5,071	5,600	528	110.4%	1,451	1,500	48	103.3%
営業外収益 Non-operating income	1,029	1,300	270	126.3%	932	1,300	367	139.4%
営業外費用 Non-operating expenses	260	200	△ 60	76.7%	121	100	△ 21	82.0%
経常利益（△：損失） Ordinary income(Δ:loss)	5,839	6,700	860	114.7%	2,262	2,700	437	119.3%
特別利益 Extraordinary gain	25	—	△ 25	—	—	—	—	—
特別損失 Extraordinary loss	114	300	185	263.0%	21	100	78	475.7%
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	5,751	6,400	648	111.3%	2,241	2,600	358	116.0%
法人税等 Current income taxes, etc.	1,669	1,700	30	101.8%	508	600	91	118.0%
当期純利益（△：損失） Net income(Δ:loss)	4,081	4,700	618	115.2%	1,732	2,000	267	115.4%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	—	—	—	—	—	—	—	—
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent	4,081	4,700	618	115.2%	1,732	2,000	267	115.4%
設備投資額（有形・無形） Capital expenditures	2,188	3,401	1,212	155.4%	758			
減価償却費（有形・無形） Depreciation and Amortization	2,196	2,400	203	109.2%	1,051	1,100	48	104.6%

（注）平成29年3月期通期実績の売上高、営業利益その他の項目の金額に関する情報は、平成30年3月期からの新セグメントに従って組み替えて表示しております。

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

	平成29年3月期 通期 実績 FY2017 Actual (a)	平成30年3月期 通期 予想 FY2018 Forecast (b)	対前期 Change from FY2017 増減 Change (b-a)	対前期 Change from FY2017 比 % (b/a)	平成29年3月期 第2四半期累計 実績 FY2017(1Q-2Q) Actual (c)	平成30年3月期 第2四半期累計 予想 FY2018(1Q-2Q) Forecast (d)	対前期 Change from FY2017(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2017(1Q-2Q) 比 % (d/c)
海外酒類事業 Overseas Alcoholic beverages business	9,402	9,300	△ 102	98.9%	4,604	4,400	△ 204	95.6%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	28,963	56,100	27,136	193.7%	10,789	27,500	16,710	254.9%
連結消去 Elimination	△ 825	△ 2,400	△ 1,574	—	△ 256	△ 900	△ 643	—
売上高 Net sales	37,540	63,000	25,459	167.8%	15,137	31,000	15,862	204.8%
売上原価 Cost of sales	25,641	44,500	18,858	173.5%	10,085	21,900	11,814	217.1%
売上総利益 Gross profit	11,899	18,500	6,600	155.5%	5,052	9,100	4,047	180.1%
運送費、保管料 Transportation and storage	1,191	1,800	608	151.0%	692	900	207	130.0%
広告宣伝費 Advertising	93	100	6	107.0%	29	100	70	333.4%
販売促進費 Sales promotion	542	600	57	110.5%	220	300	79	135.8%
管理費、その他 Other, net	6,887	12,300	5,412	178.6%	2,716	6,000	3,283	220.9%
販売費及び一般管理費 SG&A expenses	8,716	14,800	6,083	169.8%	3,659	7,300	3,640	199.5%
海外酒類事業 Overseas Alcoholic beverages business	1,738	1,600	△ 138	92.1%	748	700	△ 48	93.5%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	2,584	3,300	715	127.7%	1,124	1,600	475	142.3%
共通 Eliminations/Corporate	△ 611	△ 800	△ 188	—	△ 301	△ 300	1	—
調整額 Adjustment	△ 528	△ 400	128	—	△ 177	△ 200	△ 22	—
営業利益（△：損失） Operating income(Δ:loss)	3,182	3,700	517	116.2%	1,393	1,800	406	129.2%
営業外収益 Non-operating income	340	150	△ 190	44.0%	233	100	△ 133	42.8%
営業外費用 Non-operating expenses	142	250	107	175.6%	44	200	155	445.3%
経常利益（△：損失） Ordinary income(Δ:loss)	3,381	3,600	218	106.5%	1,582	1,700	117	107.4%
特別利益 Extraordinary gain	886	—	△ 886	—	3	—	△ 3	—
特別損失 Extraordinary loss	27	—	△ 27	—	1	—	△ 1	—
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	4,240	3,600	△ 640	84.9%	1,584	1,700	115	107.3%
法人税等 Current income taxes, etc.	1,381	1,400	18	101.3%	484	600	115	123.9%
当期純利益（△：損失） Net income(Δ:loss)	2,858	2,200	△ 658	77.0%	1,099	1,100	0	100.0%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	199	600	400	300.2%	44	300	255	670.9%
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent	2,658	1,600	△ 1,058	60.2%	1,055	800	△ 255	75.8%
設備投資額（有形・無形） Capital expenditures	763	1,096	332	143.5%	263			
減価償却費（有形・無形） Depreciation and Amortization	623	900	276	144.4%	287	450	162	156.5%
のれん償却額 Amortization of goodwill	424	320	△ 104	75.5%	205	160	△ 45	77.7%

（注）平成29年3月期通期実績の売上高、営業利益その他の項目の金額に関する情報は、平成30年3月期からの新セグメントに従って組み替えて表示しております。

④ タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

	平成29年3月期 通期 実績 FY2017 Actual (a)	平成30年3月期 通期 予想 FY2018 Forecast (b)	対前期 Change from FY2017 増減 Change (b-a)	対前期 Change from FY2017 比 % (b/a)	平成29年3月期 第2四半期累計 実績 FY2017(1Q-2Q) Actual (c)	平成30年3月期 第2四半期累計 予想 FY2018(1Q-2Q) Forecast (d)	対前期 Change from FY2017(1Q-2Q) 増減 Change (d-c)	対前期 Change from FY2017(1Q-2Q) 比 % (d/c)
研究用試薬 Research reagents	19,436	22,506	3,069	115.8%	9,557	10,271	714	107.5%
理化学機器 Scientific instruments	2,911	3,350	439	115.1%	1,220	1,080	△ 139	88.6%
受託・その他ファイン Contracted service and other	4,225	4,529	303	107.2%	1,403	1,703	299	121.4%
バイオ産業支援　計 Bioindustry	26,573	30,386	3,812	114.3%	12,180	13,055	875	107.2%
遺伝子医療 Gene Therapy	500	500	—	100.0%	—	—	—	—
医食品バイオ AgriBio	2,301	2,313	11	100.5%	1,018	993	△ 25	97.5%
売上高 Net sales	29,375	33,200	3,824	113.0%	13,199	14,049	849	106.4%
売上原価 Cost of sales	12,422	13,726	1,303	110.5%	5,152	5,735	582	111.3%
売上総利益 Gross profit	16,952	19,473	2,520	114.9%	8,046	8,313	267	103.3%
運送費、保管料 Transportation and storage	594	601	6	101.0%	300	292	△ 8	97.3%
広告宣伝費 Advertising	89	74	△ 14	84.0%	45	37	△ 8	81.3%
販売促進費 Sales promotion	854	846	△ 8	99.0%	428	426	△ 1	99.6%
研究開発費 Research and development	4,101	4,868	767	118.7%	1,904	2,265	360	118.9%
管理費、その他 Other, net	8,110	9,782	1,672	120.6%	3,989	4,804	814	120.4%
販売費及び一般管理費 SG&A expenses	13,749	16,173	2,423	117.6%	6,669	7,826	1,156	117.3%
バイオ産業支援 Bioindustry	6,218	6,594	376	106.1%	3,028	2,345	△ 683	77.4%
遺伝子医療 Gene Therapy	△ 1,380	△ 1,472	△ 92	—	△ 775	△ 862	△ 87	—
医食品バイオ AgriBio	104	121	16	115.9%	△ 10	△ 21	△ 11	—
共通 Eliminations/Corporate	△ 1,739	△ 1,943	△ 203	—	△ 865	△ 973	△ 108	—
営業利益（△：損失） Operating income(Δ:loss)	3,202	3,300	97	103.0%	1,377	487	△ 889	35.4%
営業外収益 Non-operating income	445	356	△ 89	80.0%	98	75	△ 22	77.1%
営業外費用 Non-operating expenses	68	56	△ 12	81.4%	32	39	7	121.9%
経常利益（△：損失） Ordinary income(Δ:loss)	3,579	3,600	20	100.6%	1,443	523	△ 919	36.3%
特別利益 Extraordinary gain	2	—	△ 2	—	2	—	△ 2	—
特別損失 Extraordinary loss	775	309	△ 466	39.9%	12	6	△ 5	55.0%
税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes	2,805	3,290	484	117.3%	1,433	517	△ 916	36.1%
法人税等 Current income taxes, etc.	1,492	1,429	△ 20	98.6%	932	502	△ 270	65.0%
当期純利益（△：損失） Net income(Δ:loss)	1,356	1,861	505	137.2%	661	14	△ 646	2.2%
非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	3	11	8	341.9%	△ 6	△ 4	2	—
親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent	1,352	1,850	497	136.7%	667	18	△ 648	2.8%
設備投資額（有形・無形） Capital expenditures	1,648	1,703	54	103.3%	573			
減価償却費（有形・無形） Depreciation and Amortization	1,722	2,473	751	143.6%	856	1,176	320	137.4%
のれん償却額 Amortization of goodwill	162	596	433	367.3%	83	282	199	337.8%

8. 平成30年3月期 参考資料 :Reference Data for the year ending March 31, 2018

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用):Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成29年3月期 FY2017	平成30年3月期 FY2018 / Apr. 1, 2017 - Mar. 31, 2018	
	実績 Actual (a)	予想 Forecast (b)	前期差 Change(b-a)
米ドル : US dollar	108.81	105.00	△ 3.81
ポンド: Pound	147.64	131.00	△ 16.64
ユーロ: Euro	120.30	116.00	△ 4.30
人民元: Yuan	16.36	15.50	△ 0.86
100ウォン: 100 Won	9.37	8.80	△ 0.57
インドルピー: Rupee	1.62	1.60	△ 0.02
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	12.72	11.60	△ 1.12
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	78.76	75.00	△ 3.76
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	—	79.00	—

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2017
海外酒類事業 Overseas Alcoholic beverages business	△ 436
海外日本食材卸事業 Japanese food wholesale business in overseas markets	△ 1,545
連結消去 Elimination	53
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ計 Net sales of Takara Shuzo International Group	△ 1,927
研究用試薬 Research reagents	△ 709
理化学機器 Scientific instruments	△ 45
受託・その他 Contracted service and other	△ 62
バイオ産業支援 計 Bioindustry	△ 817
遺伝子医療 Gene Therapy	—
医食品バイオ AgriBio	—
タカラバイオグループ 計 Net sales of Takara Bio Group	△ 817
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	△ 2,745

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	平成29年3月期通期実績 FY2017 Actual			平成30年3月期通期予想 FY2018 Forecast		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo Co., Ltd.	149,452	—	—	153,000	—	—
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	37,540	37,272	99.3%	63,000	63,000	100.0%
タカラバイオグループ Takara Bio Group	29,375	14,813	50.4%	33,200	18,771	56.5%
その他および調整額 Other / Adjustment	17,824	—	—	18,800	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	234,193	52,086	22.2%	268,000	81,771	30.5%

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

		平成29年3月期 実績 FY2017 Actual		平成30年3月期 予想 FY2018 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	32,782	4,750	34,800	4,798
Takara Sake USA Inc.	百 万 円 :Millions of Yen	3,567	516	3,654	503
宝酒造食品	千 元 :Thousands of Yuan	46,997	2,404	48,434	2,469
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	768	39	750	38
トマーチン	千 ポ ン ド :Thousands of Pound	14,509	3,364	14,982	3,419
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	2,142	496	1,962	447
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ド ル :Thousands of US dollar	20,479	7,774	20,829	7,899
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	2,228	845	2,187	829
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	133,913	15,764	147,159	16,915
FOODEX Group	百 万 円 :Millions of Yen	16,109	1,896	17,070	1,962
タザキフーズ	千 ポ ン ド :Thousands of Pound	34,481	1,995	37,300	2,100
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	5,090	294	4,886	275
ミューチャルトレーディング	千 US ド ル :Thousands of US dollar	70,919	3,596	292,000	9,259
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	7,762	393	30,660	972
ニッポンフード	千 AUS ド ル :Thousands of Australian dollar	―	―	46,216	1,723
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	―	―	3,651	136
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.	千 ユ ー ロ :Thousands of Euro	19,372	2,299	25,227	2,763
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	2,330	276	2,926	320
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟAB	千 SEK :Thousands of Sweden Krona	28,009	Δ 15,329	67,875	6,691
Takara Bio Europe AB	百 万 円 :Millions of Yen	356	Δ 194	787	77
宝生物工程(大連)	千 元 :Thousands of Yuan	305,664	124,340	221,837	42,061
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	5,000	2,034	3,438	651
宝日医生物技術(北京)	千 元 :Thousands of Yuan	135,179	3,737	334,154	38,294
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	2,211	61	5,179	593
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	8,921	1,250	9,995	1,386
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	835	117	879	122
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	196,570	Δ 581	232,970	3,108
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	318	Δ 0	372	4
タカラバイオUSA	千 US ド ル :Thousands of US dollar	75,697	16,996	111,725	15,760
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	8,236	1,849	11,731	1,654

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo Co., Ltd.

(百万円 :Millions of Yen)

	対前期増減 Change from FY2017		
	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price
売上総利益 計 Gross profit	+2,025	+1,486	+539
(主な内訳)			
焼酎 Shochu	Δ 617	Δ 657	+40
清酒 Sake	+301	+413	Δ 111
ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers	+1,765	+1,598	+167
本みりん Hon Mirin	+424	Δ 318	+743
(参考)原価コストダウン Reference :Cost reduction	+28	※上記数量差および単価差に含む *Included in changes above	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)業績予想(p.14)における「その他」の内訳 :Breakdown of "Other" segment in the Financial forecast of Takara Holdings Inc. (p.14)

	平成29年3月期 実績 FY2017 Actual		平成30年3月期 予想 FY2018 Forecast	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	19,318	951	19,631	980
宝ヘルスケア Takara Healthcare	1,766	12	1,845	75
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	461	389	467	399
その他 Other	17,470	813	17,056	845
「その他」計 Total "Other"	39,017	2,167	39,000	2,300